Introduction {#s1}
============

The formation of the vertebrate skeleton and associated musculature relies on the ordered and timely segmentation of mesodermal tissue during early embryonic development. Segmentation is progressive and occurs in an anterior to posterior direction as the body axis elongates (reviewed in [@bib52]). Mesodermal segments, or somites, 'pinch off' at the rostral limit of the two rods of pre-somitic mesoderm (PSM) that lie on either side of the caudal neural tube, with a distinct, species-specific periodicity; every 90 min in the chicken and every 120 min in the mouse. This periodicity is regulated by a molecular oscillator, known as the segmentation clock, that is defined by cyclic gene expression within PSM tissue with a period that regulates somite formation. These 'clock' genes belong to the Notch, WNT and FGF signalling pathways and are expressed in a cyclical pattern in the PSM of a wide variety of vertebrate species ([@bib39]; reviewed in [@bib13]; [@bib22]; [@bib45]). On a single cell level in the vertebrate PSM, oscillatory gene expression is believed to be established through negative feedback loops of unstable clock gene products.

Previous mathematical models of the somitogenesis clock that invoke the mechanism of delayed negative feedback predict that the clock period can be approximated as a sum of the delays involved in processes such as transcription, splicing, translation and transport and the half-lives of inhibitors of clock gene expression ([@bib41]; [@bib48]; [@bib2]; [@bib25]). Subsequent studies have confirmed that the period can be altered by genetically modifying genes that encode negative regulators (e.g., Hes7, Her6, Her7, Nrarp) ([@bib27]; [@bib57]; [@bib36]; [@bib63]; [@bib52]; [@bib26]; [@bib31]). Moreover, it has been shown that regulation of clock gene mRNA turnover and degradation is gene specific and regulated at the level of the 3′UTR ([@bib28]; [@bib50]). In contrast, there has been relatively little experimental work demonstrating the predicted role of protein stability in regulating the periodicity of clock gene oscillations ([@bib29]).

It is notable that models that invoke delayed negative feedback as the mechanism underlying the somitogenesis clock were developed primarily from zebrafish data, where the clock period is relatively short and there are significantly fewer oscillating components than other vertebrate species ([@bib39]). Moreover, in zebrafish there is experimental evidence that Notch plays a key role in the synchronisation of neighbouring oscillators ([@bib12]) but that it is not necessary for oscillations themselves ([@bib53]). In contrast, Notch signalling in mouse and chick is thought to be essential for oscillations ([@bib16]). One crucial factor in this regard is the Notch1 intracellular domain (NICD) which is cleaved following ligand activation, translocates to the nucleus and activates Notch target gene expression. NICD is unstable and, at least in mouse, its production appears as pulsatile, spatio-temporal waves that traverse the rostro-caudal axis of the PSM in the manner of a clock gene ([@bib33]). Importantly, pulsatile Notch1 protein expression was recently shown to be dependent on Notch signalling in the PSM of both chick and mouse ([@bib5]); this raises the possibility that, in mouse and chick at least, positive feedback, mediated by Notch and NICD, plays a role in the clock mechanism.

In this study we develop a mathematical model of the clock that describes both repression and NICD-mediated activation of clock gene transcription. The model predicts that increasing the half-life of NICD results in elevated levels of NICD and a longer clock period. Notably, these effects are not observed in the model upon increasing the half-life of the repressing clock protein. To test the predictions, we use a pharmacological approach that robustly delays the phase patterns of a clock gene in the chick and mouse PSM. Under these conditions, using a custom made antibody that recognises endogenous chick NICD, we show that, concomitant to delaying the pace of oscillations, the inhibitors increase both levels of NICD and its half-life. In agreement with model predictions, we rescue the phase patterns of clock gene expression by reducing NICD production. These data therefore suggest that increasing the half-life of NICD and thus increasing its turnover time increases the period of the somitogenesis clock.

Results {#s2}
=======

Mathematical modelling predicts that increased NICD half-life results in higher levels of NICD and a longer clock period {#s2-1}
------------------------------------------------------------------------------------------------------------------------

In order to investigate the role of both positive and negative feedback in the circuitry of the somitogenesis clock, we developed a mathematical model in which the key regulatory interactions are that an inhibitory clock protein and NICD negatively and positively regulate gene transcription, respectively (see 'Materials and methods' and [Figure 1A,B](#fig1){ref-type="fig"}). Hence in the absence of clock protein but presence of NICD, transcription occurs. Conversely, transcription is inhibited when there are high levels of inhibitor and low levels of activator.10.7554/eLife.05842.003Figure 1.A mathematical model of positive and negative regulation of the somitogenesis clock.(**A**) A schematic illustration of inter-cellular coupling via Delta-Notch signalling. (**B**) A schematic illustration of the reduced model in which the pulsatile production of NICD is down stream of clock gene expression. (**C**--**E**) Representative numerical solution of the model [Equations (1)](#equ1){ref-type="disp-formula"}-[(3)](#equ3){ref-type="disp-formula"}. Clock protein (p(t), solid line) and NICD (n(t), dashed line) levels are plotted against time. (**C**) \'Wild-type\' oscillations (k_4 = 0.063), (**D**) Decreasing NICD decay rate yields longer period oscillations (k_4 = 0.023), (**E**) Decreasing Hes7 decay rate lowers levels of Hes7 and NICD (k_2 = 0.035). (**F**) The oscillation period (colour) is plotted against Hes7 and NICD half-lives. (**G**) NICD level is plotted against Hes7 and NICD half-lives. (**H**) Oscillator period is plotted against NICD production rate and half-life. (**E**--**G**) Solid lines depict emergence of the non-trivial steady-state. Dashed lines depict points in parameter space where the nontrivial steady state undergoes a Hopf bifurcation. Damped Oscillations (DO), Stable Oscillations (SO), No Oscillations (NO). Unless otherwise stated, parameter values are: *k*~1~=123 min^−1^, *k*~2~=0.058 min^−1^, *k*~3~=134 min^−1^, *k*~4~=0.063 min^−1^, *T*~1~=44.0 min, *T*~2~=67.0 min, *K*~*P*~=125, *K*~*N*~=125.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.003](10.7554/eLife.05842.003)

In [Figure 1C](#fig1){ref-type="fig"} we plot a representative numerical solution of the model. In a given cycle of the clock, NICD activates transcription, resulting in the production of cytoplasmic protein after some delay, *T*~1~. Clock protein then represses transcription and after a further delay, *T*~2~ , NICD is produced and activates the next cycle of the clock. In the model, perturbing protein half-lives alters the balance between activation and repression in a manner that modifies the clock period. In [Figure 1D](#fig1){ref-type="fig"} we show that increasing the NICD half-life increases the period of the oscillation and the levels of both NICD and clock protein. In [Figure 1E](#fig1){ref-type="fig"} we show that increasing the clock protein half-life does not greatly affect the oscillator period but reduces levels of NICD.

In order to further explore model behaviour we calculated solutions of the model in different regions of parameter space. In [Figure 1F,G](#fig1){ref-type="fig"} we show that the oscillator period and levels of NICD increase with NICD half-life but that these effects are not seen upon increasing the clock protein half-life. In [Figure 1H](#fig1){ref-type="fig"} we show that the increased period, arising as a consequence of increased NICD half-life, can be rescued by reducing the NICD production rate. These numerical solutions demonstrate that, in the model, the balance between NICD production and degradation rates plays a key role in determining the clock period. Additionally, we note that there is a critical value of the production rate below which the trivial steady-state becomes stable (solutions tend to zero) and that perturbing clock protein and NICD production and decay rates can drive the system into stable states (e.g., by increasing repressor half-life in [Figure 1F](#fig1){ref-type="fig"} or reducing the NICD production rate in [Figure 1H](#fig1){ref-type="fig"}).

Wnt inhibition delays the pace of *cLfng* oscillations in the chick and mouse PSM {#s2-2}
---------------------------------------------------------------------------------

It has previously been reported that modulating either the Shh or Wnt pathways can affect the pace of clock gene oscillations in the PSM ([@bib21]; [@bib56]; [@bib23]). To experimentally test the predictions of our model, we used a half-embryo assay to investigate whether levels and half-life of NICD were elevated under conditions where clock gene oscillations were robustly delayed using a pharmacological approach (see 'Materials and methods'; [@bib21]). In the first instance, PSM explants from chick embryos between Hamburger Hamilton (HH) stages 10--12 were exposed to XAV939, a specific Wnt inhibitor that acts by inhibiting Tankyrase1 (TNK1) and TNK2 enzymes, which normally degrade Axin2. Hence upon treatment with XAV939, AXIN2 protein is stabilised and maintains phosphorylated β-catenin protein in the destruction complex ([@bib32]).

Following a titration assay, we determined that 100 μM XAV939 treatment was the lowest concentration that caused robust and reproducible down regulation of the Wnt target genes *cAxin2* and *cLef1* compared to the corresponding DMSO-treated contralateral explants ([Figure 2---figure supplement 1C,D](#fig2s1){ref-type="fig"}; n = 61/68; [@bib5]) and led to increased levels of phosphorylated β-catenin at Ser33, Ser37, Thr41, as expected ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; n = 8/10). Using the same assay, we investigated the effect of the inhibitor on the dynamic expression of *cLfng* in the PSM*.* Following exposure to 100 μM XAV939, the domain of *cLfng* expression was at least 1 phase behind that of the control explant ([Figure 2A](#fig2){ref-type="fig"}, M; n = 57/64) and occasionally this resulted in the treated explant forming one less somite boundary than the control explant. These data imply that 100 μM XAV939 treatment noticeably lengthens the period of the oscillations. In explant pairs where both sides were DMSO-treated, an asymmetric pattern of *cLfng* expression was rarely seen (n = 2/18, data not shown) and, as such, the effects of XAV939 on *cLfng* expression could not be attributed to DMSO, natural variability in expression, or to the assay itself. In order to ensure that the oscillations were delayed and not halted, a fix and culture assay (see 'Materials and methods') revealed that *cLfng* expression was still dynamic in the presence of 100 μM XAV939 ([Figure 2B](#fig2){ref-type="fig"}; n = 8/9). Furthermore, Phospho-histone H3 (pH3) and NucView analyses demonstrated that neither proliferation nor apoptosis, respectively, were significantly affected following drug treatment ([Figure 2---figure supplement 2A,D](#fig2s2){ref-type="fig"}; n = 4, p = 0.236; n = 4, p = 0.292). These data clearly demonstrate that Wnt inhibition delays the period of the segmentation clock in the chick PSM. Using the same half-embryo inhibitor assay in the mouse embryo, we found that exposure to 100 μM XAV939 delayed the pace of *mLfng* oscillations as compared to control DMSO-treated E10.5 half PSM explants ([Figure 2I](#fig2){ref-type="fig"}; n = 19/26). Moreover, a fix and culture assay revealed that *mLfng* expression was still dynamic in the presence of 100 μM XAV939 ([Figure 2J](#fig2){ref-type="fig"}; n = 12/20).10.7554/eLife.05842.004Figure 2.XAV939, Roscovitine, DRB and PHA767491 treatment delays the pace of the segmentation clock in the chick and mouse PSM.Bissected chick or mouse caudal explant pairs treated '−' or '+' inhibitor (**A**, **C**, **E**, **G**) or treated with inhibitor and subjected to the fix and culture assay (**B**, **D**, **F**, **H**) and then analysed by in situ hybridisation for *Lfng* mRNA expression : (**A**, **C**, **E**, **G**) Treatment of chick PSM explants in the presence (+) or absence (−) of XAV939 (**A**), Roscovitine (**C**), DRB (**E**) and PHA7667491 (**G**) for 3 hr reveals that '+' explants have lagging expression of *cLfng*, often with one less somite formed than the '−' explants. (**B**, **D**, **F**, **H**): After 3 hr treatment in the presence of XAV393 (**B**), Roscovitine (**D**), DRB (**F**) and PHA767491 (**H**), one chick PSM explant was fixed while the other was treated for another 45 min, showing that *cLfng* expression is still dynamic in the presence of these inhibitors. (**I**, **K**): Mouse PSM explants treated in the presence or absence of XAV939 (**I**) or Roscovitine (**K**) for 4 hr revealed a delay in the oscillations of *mLfng* expression. (**J**, **L**): Treatment of one mouse PSM explant for 4 hr, and the other for 5 hr in the presence of XAV939 (**J**) or Roscovitine (**L**) reveals that *mLfng* mRNA expression is still oscillating in the PSM. The red arrowheads identify the somites that have formed during the in vitro culture period of the assay. (**M**) Schematic representation of the expression domains of *Lfng* in the PSM in the three different phases of one oscillation cycle. S1, SII = the most recently formed somite. (P) = previous cycle.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.004](10.7554/eLife.05842.004)10.7554/eLife.05842.005Figure 2---figure supplement 1.XAV939, Roscovitine, DRB treatment down-regulates expression of the Wnt target Axin2 and the Shh target Gli1 in the chick PSM.(**A**): Western Blot analysis of pooled PSM lysates from half PSM explants treated '+' or '−' the inhibitors using antibodies against phosphorylated β-catenin, reveals levels of this form of β-catenin is increased in the chick PSM after 3 hr treatment with XAV939 (mean fold-change = 2.856, p = 0.016), but unaffected after 3 hr treatment with Roscovitine (mean fold-change =1.134, p = 0.617) or DRB (mean fold-change = 0.785). (**B**): Similar analysis looking at levels of RNA Polymerase which is phosphorylated at Serine 2 (Ser2) reveal this modification appears unaffected by 3 hr treatment with Roscovitine, DRB or PHA767491, but levels of RNA polymerase phosphorylated at Serine 5 (Ser5) are somewhat decreased following this treatment. (**C**): Bissected chick caudal explant pairs treated '−' or '+' the inhibitors and then analysed by in situ hybridisation show expression of *cLef1* is down-regulated after 3 hr treatment in the presence of XAV939 in the chick PSM. (**D**--**F**): Expression of the cAxin2 is similarly down-regulated in the chick PSM after 3 hr treatment in the presence of XAV939 (**D**), Roscovitine (**E**), or DRB (**F**). (**G**--**I**): Expression of *cGli1* is also down-regulated after 3 hr treatment in the presence of XAV939 (**G**), Roscovitine (**H**), or DRB (**I**).**DOI:** [http://dx.doi.org/10.7554/eLife.05842.005](10.7554/eLife.05842.005)10.7554/eLife.05842.006Figure 2---figure supplement 2.XAV939, Roscovitine, DRB treatment does not induce apoptosis or affect cell proliferation in the chick PSM.(**A**--**C**): Mean numbers of phospho-histone3 (Ph3)-positive cells in the chick PSM are not significantly affected after 3 hr treatment with XAV939 (**A**), Roscovitine (**B**), or DRB (**C**). (**D**--**F**): Mean numbers of NucView-positive cells in the in the chick PSM are not significantly affected after 3 hr treatment with XAV939 (**D**), Roscovitine (**E**), or DRB (**F**).**DOI:** [http://dx.doi.org/10.7554/eLife.05842.006](10.7554/eLife.05842.006)10.7554/eLife.05842.007Figure 2---figure supplement 3.XAV939, Roscovitine, DRB and PHA-767491 treatment delays dynamic mRNA expression of Notch target clock genes in the chick PSM thereby extending the clock period.(**A**--**D**): Bissected chick caudal explant pairs treated '−' or '+' the inhibitors and then analysed by in situ hybridisation for the Notch target gene *cHairy2* reveals *cHairy2* mRNA expression is delayed in the treated side as compared to the control after 3 hr treatment with XAV939 (**A**), Roscovitine (**B**), DRB (**C**), PHA-767491 (**D**). (**E**--**J**): Bissected chick caudal explant pairs treated for 3 hr '−' or '+' the inhibitors and then subjected to fix and culture where the cultured side is cultured for 90 min (**E**, **F**) or 2 hr (**G**--**J**) and then analysed by in situ hybridisation for *cLfng* mRNA expression. Red arrows indicate newly formed somites from the beginning of treatment.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.007](10.7554/eLife.05842.007)

Shh inhibition does not delay the pace of *cLfng* oscillations in the chick PSM {#s2-3}
-------------------------------------------------------------------------------

Similarly, we directly perturbed the Shh pathway in the half-embryo assay using Cyclopamine, a well-established inhibitor of Shh signalling. At 25 μM, Cyclopamine abolished expression of the Shh target gene *cGli1* in the chicken half-PSM explant compared to the DMSO control ([Figure 3A](#fig3){ref-type="fig"}; n = 5/5). Surprisingly, and in contrast to published data ([@bib56]), *cLfng* expression in the PSM was not delayed at either 25 μM ([Figure 3B,D](#fig3){ref-type="fig"}; n = 6/9) or 50 μM ([Figure 3C,D](#fig3){ref-type="fig"}; n = 3/4). This assay suggests that Shh signalling does not play a direct role in the regulation of the segmentation clock.10.7554/eLife.05842.008Figure 3.Cyclopamine treatment does not affect the pace of *cLfng* oscillations in the chick PSM.Bissected chick caudal explant pairs treated '−'or '+' cyclopamine and then analysed by in situ hybridisation for *Lfng* or *Gli1* mRNA expression. (**A**): At 25 µM, cyclopamine inhibits expression of the Shh target gene *cGli1* in the chick PSM after 3 hr treatment. (**B**, **C**): The expression domains and intensity of *cLfng* mRNA are the same in the PSM of the '−' or '+' cyclopamine halves of each embryo and there is no difference in the number of somites in each half of a pair thus we conclude the pace of *Lfng* oscillation is not affected by cyclopamine treatment for 3 hr at either 25 µM (**B**) or 50 µM (**C**). (**D**) Schematic representation of the expression domains of *Lfng* in the PSM in the three different phases of one oscillation cycle. S1, SII = the most recently formed somite.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.008](10.7554/eLife.05842.008)

Exposure to XAV939 increases the level of cNICD in the chick and mouse PSM {#s2-4}
--------------------------------------------------------------------------

Given our results with the Wnt inhibitor and that NICD stability is known, in other contexts, to be regulated by GSK3B ([@bib14]; [@bib35]; see also [@bib18]), we investigated whether the effect upon the period was associated with a change in levels of NICD, as the model predicted. To that end we generated a polyclonal anti-cNICD antibody raised against the chicken N-terminal sequence of the cleaved chicken Notch1 intracellular domain. The epitope is only exposed after gamma secretase cleavage and is not accessible in the un-cleaved form. After confirming specificity by Western Blotting against recombinant cNICD protein ([Figure 4A](#fig4){ref-type="fig"}, lanes 1, 2), we cultured half-PSM explant pairs in the presence of the γ-secretase inhibitor LY411575 ([@bib40]) or DMSO for 3 hr. Western Blot revealed a specific band against endogenous cNICD that ran at the same size as recombinant cNICD protein and at the predicted molecular weight of ∼87 kDa in the DMSO control pool which was abolished in the +LY411575 treated pool, thereby validating the specificity of the antibody ([Figure 4A](#fig4){ref-type="fig"}, lanes 3, 4; [Figure 4D](#fig4){ref-type="fig"}, lanes 1, 2). We performed immunohistochemistry on sagittal sections of chick PSM tissue to analyse the spatial localisation profile of NICD in this tissue and found it to exhibit a very similar profile to that described for mNICD in the mouse PSM ([@bib33]). Thus cNICD is produced in (and cleared from) discrete domains of the PSM in a manner reminiscent of the expression profile of clock genes in different phases of the cycle ([Figure 4B](#fig4){ref-type="fig"}).10.7554/eLife.05842.009Figure 4.cNICD levels in the chick PSM are elevated after exposure to XAV939, Roscovitine, DRB or PHA767491.(**A**): A polyclonal cNICD antibody was raised against the N-term sequence of the cleaved chicken Notch1 intracellular domain. The epitope is only exposed after gamma secretase cleavage and is not accessible in the uncleaved form. By Western Blot analysis the antibody detects a band of protein at around 90KDa (see arrow) in an *in vitro*-generated recombinant cNICD sample, which is not detected in the control IVT sample; this band disappears in half chick PSM pools (see 'Materials and methods') after 3 hr treatment with 150 nM LY411575, a concentration shown previously to have no toxic effects to PSM tissue ([@bib5]). (**B**): Immunohistochemistry for cNICD protein on 16 μm sagittal sections of sucrose agar embedded HH10 chicken embryo tails showing dynamic phases of localisation in the PSM and schematic representations to the right of each panel. S1 - S3 = somite; S0 - S-1 = prospective somite region of anterior PSM. (**C**): A schematic illustrating the cNICD degradation assay: corresponding pools of 9 PSM explants are incubated in the presence or absence of an inhibitor for 3 (chick) or 4 hr (mouse), before treating all pools with the protein synthesis inhibitor cycloheximide (CHX) for a further hour. Lysates are then collected for Western Blot analysis. (**D**): Representative Western Blot showing levels of cNICD protein in lysates of chick PSM pools are increased after treatment with XAV939, Roscovitine, DRB and PHA767491, but not with cyclopamine. Lanes 1 and 2 show exposure to 150 nM LY411575 alone for 3 hr removes all NICD and serves as a control for the western. Lanes 3 and 4 show exposure to CHX alone in the last hour of culture severely depletes NICD levels as compared to NICD levels in the pool of contralateral PSM explants cultured in DMSO. (**E**): Levels of mNICD in the mouse PSM pools are increased following treatment with XAV939. Lanes 1 and 2 show that NICD protein levels drop drastically after exposure for 1h to CHX as compared to strong NICD signal in lysate from the contralateral half PSMs treated with EtOH. (**F**): Representative Western Blot showing levels of cNICD protein in lysates of chick PSM pools are increased after treatment with XAV939, Roscovitine and DRB when LY411575 is added to the culture for the last hour (in place of CHX). Lanes 1 and 2 show exposure to LY411575 alone only in the last hour severely depletes NICD levels as compared to the NICD levels in the pool of contralateral PSM explants cultured in DMSO.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.009](10.7554/eLife.05842.009)10.7554/eLife.05842.010Figure 4---figure supplement 1.XAV939, Roscovitine, and DRB treatment increases the level of cNICD in the chick PSM.(**A**): A schematic showing the degradation assay notably without the cycloheximide step described in the assay for [Figure 4](#fig4){ref-type="fig"}: pools of 9 explants were treated either in the presence or absence of inhibitors for 3 hr before lysis. (**B**--**D**): After the treatment depicted in (**A**), Western Blot analysis revealed levels of cNICD are elevated in chick PSM explant pools after treatment with XAV939, p = 0.0361 (**B**), Roscovitine, p = 0.00653 (**C**), or DRB, p = 0.00601 (**D**) relative to their respective DMSO control treated pools.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.010](10.7554/eLife.05842.010)

To investigate if exposure to XAV939 affects the levels of endogenous cNICD, chick embryos were bissected as before and contralateral sides pooled. For each reagent, one pool was cultured for 3 hr in DMSO and the other was cultured in the inhibitor. In order to cease production of new NICD, both control and inhibitor treated pools were cultured for an additional hour in the presence of cycloheximide ([Figure 4C](#fig4){ref-type="fig"}). Lysates were then analysed by Western Blot for NICD. Strikingly, we observed that the level of cNICD protein was increased significantly in the presence of XAV939 ([Figure 4D](#fig4){ref-type="fig"}, lanes 5, 6; n = 7/9; [Table 1](#tbl1){ref-type="table"}) compared to the corresponding DMSO control pool where the resident cNICD had degraded substantially in the presence of cycloheximide. For each assay, additional control explants confirmed that: i) *Lfng* was delayed in inhibitor treated explants; and ii) samples cultured for 3 hr in the absence of inhibitor and then for the last hour in cycloheximide alone showed a reduction in levels of NICD when compared to contralateral explants cultured in Ethanol for the last hour ([Figure 4D](#fig4){ref-type="fig"}, lanes 3, 4). Notably, even in the absence of cycloheximide ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), levels of cNICD in the chicken PSM were consistently higher when treated with XAV939 ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}; n = 5/5; [Table 1](#tbl1){ref-type="table"}) compared to respective DMSO control lysates, although the mean fold-change increase was slightly less. These assays reveal that exposure to XAV939 elevates the level of cNICD protein in the chicken PSM, just as it delays oscillations of the Notch target gene *cLfng*. Significantly, exposure to Cyclopamine did not affect the levels of cNICD in treated PSM explants just as it did not affect the pace of *cLfng* oscillations in this tissue ([Figure 4D](#fig4){ref-type="fig"}, lanes 13, 14; n = 2/2; [Table 1](#tbl1){ref-type="table"}).10.7554/eLife.05842.011Table 1.Summary table of densitometry quantifications for cNICD and mNICD in inhibitor assays**DOI:** [http://dx.doi.org/10.7554/eLife.05842.011](10.7554/eLife.05842.011)TreatmentNMean adjusted relative fold change of cNICD protein± standard error of the meanStatistical testp-valueXAV93993.078±0.776One-sample T-test0.0280[\*](#tblfn1){ref-type="table-fn"}XAV939 (no CHX)52.491±0.480One-sample T-test0.0361[\*](#tblfn1){ref-type="table-fn"}Roscovitine101.94±0.255One-sample Signed Rank test0.002[\*](#tblfn1){ref-type="table-fn"}Roscovitine (no CHX)71.594±0.146One-sample T-test0.00653[\*](#tblfn1){ref-type="table-fn"}DRB82.557±0.702One-sample Signed Rank test0.008[\*](#tblfn1){ref-type="table-fn"}DRB (no CHX)61.369±0.081One-sample T-test0.00601[\*](#tblfn1){ref-type="table-fn"}Cyclopamine21.263±0.106One-sample T-test0.244PHA76749123.479±0.451One-sample T-test0.115MLN492438.831±2.734One-sample T-test0.103TreatmentNMean adjusted relative fold change of mNICD protein± Standard error of the meanStatistical testp-valueXAV93982.221±0.396One-sample signed rank test0.008[\*](#tblfn1){ref-type="table-fn"}[^3][^4]

Given the consistent effect of 100 μM XAV939 upon both *cLfng* and *mLfng* oscillations, we used the same assay to investigate whether this reagent also affected levels of mNICD in the mouse PSM, with the initial culture period extended to 4 hr to allow for the longer clock period in the mouse embryo. Strikingly, we observed that the level of mNICD protein in the PSM was increased significantly in the presence of XAV939 ([Figure 4E](#fig4){ref-type="fig"}, lanes 3, 4; n = 8) compared to the corresponding DMSO control pool of half PSM explants, where mNICD levels had dropped substantially in the presence of cycloheximide ([Figure 4E](#fig4){ref-type="fig"}, lanes 1, 2; [Table 1](#tbl1){ref-type="table"}). Thus, the effect of XAV939 to delay the pace of *Lfng* oscillations across the PSM and to increase the level of NICD in the PSM is conserved in both chick and mouse.

Cyclin dependent kinase inhibitors delay the pace of *Lfng* oscillations in the PSM {#s2-5}
-----------------------------------------------------------------------------------

Previous studies have shown that the stability of NICD in other contexts can be regulated by cyclin dependent kinase (CDK) mediated phosphorylation ([@bib19]). Given the prediction of the mathematical model that modification of NICD stability can influence the period of the clock, we investigated whether perturbing CDK signalling would affect either clock gene oscillations and/or levels of NICD in the chick PSM. To that end, we directly perturbed the CDK pathway in the half-embryo assay using the CDK inhibitor Roscovitine. Roscovitine is a 2,6,9-substituted purine analogue that competes with ATP for the active binding site on CDKs ([@bib42]).

We found that Roscovitine treatment at 10 µM clearly delayed oscillation of *cLfng* expression relative to the DMSO control ([Figure 2C](#fig2){ref-type="fig"}; n = 59/62) whilst the fix and culture assay confirmed that *cLfng* expression was still oscillatory ([Figure 2D](#fig2){ref-type="fig"}; n = 8/10). Neither proliferation ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}; n = 5, p = 0.204) nor apoptosis ([Figure 2---figure supplement 2E](#fig2s2){ref-type="fig"}; n = 4, p = 0.886) were significantly affected in the PSM. However, exposure to 100 or 300 μM Roscovitine severely impacted both proliferation and apoptosis and strongly down-regulated or abolished *cLfng* expression (data not shown). These findings reveal that the oscillations of *cLfng* expression in the chicken PSM are slowed by Roscovitine treatment at a concentration that does not appear to affect cell proliferation. Moreover, we found that exposure to 10 μM Roscovitine delayed the pace of *mLfng* oscillations as compared to control DMSO-treated E10.5 mouse half PSM explants ([Figure 2K](#fig2){ref-type="fig"}; n = 20/22). The fix and culture assay revealed that *mLfng* expression was still dynamic in the presence of 10 μM Roscovitine ([Figure 2L](#fig2){ref-type="fig"}; n = 8/10).

Roscovitine is a broad spectrum CDK inhibitor. We used an additional two CDK inhibitors reported to specifically reduce the kinase activities of CDK7/CyclinH and CDK9/CyclinT towards the C-terminal domain (CTD) of RNA pol II: 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB; a nucleoside analogue) and PHA-767491. We found that exposure of chick half-PSM explants to 10 μM DRB delayed *cLfng* oscillation phase compared to the control explant ([Figure 2E](#fig2){ref-type="fig"}; n = 67/73) and the fix and culture assay confirmed that *cLfng* expression was still oscillatory in the PSM at this concentration ([Figure 2F](#fig2){ref-type="fig"}; n = 15/18). Western Blotting analysis confirmed that phosphorylation of Serine 5 on the CTD of RNA pol II was reduced by 10 μM DRB treatment ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}; n = 3/3; mean fold change = 0.709). Neither proliferation ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"}; n = 5, p = 0.884) nor apoptosis ([Figure 2---figure supplement 2F](#fig2s2){ref-type="fig"}; n = 3, p = 0.844) were significantly affected. Similarly, exposure to 1 μM PHA-767491 reduced phosphorylation of Serine 5 on the CTD of RNA pol II ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}; n = 2; mean fold change = 0.709), delayed *cLfng* oscillation phase compared to the control half-PSM ([Figure 2G](#fig2){ref-type="fig"}; n = 13) and the fix and culture assay confirmed that *cLfng* expression was still oscillatory in the PSM at this concentration ([Figure 2H](#fig2){ref-type="fig"}; n = 6). Another cycling Notch target, *cHairy2,* was also consistently delayed compared to the respective DMSO control when treated with either XAV939 ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}; n = 4/6), Roscovitine ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}; n = 6/7), DRB ([Figure 2---figure supplement 3C](#fig2s3){ref-type="fig"}; n = 5/6) or PHA-767491 (n = 8/8; [Figure 2---figure supplement 3D](#fig2s3){ref-type="fig"}). These data demonstrate that a panel of CDK inhibitors robustly delays Notch target clock gene oscillations in the PSM in a similar way to that seen following Wnt inhibition and that these effects are separable from the cell cycle.

The CDK inhibitors do not appear to affect clock period via inhibition of canonical Wnt signalling {#s2-6}
--------------------------------------------------------------------------------------------------

In order to investigate whether the CDK inhibitors all act through the Wnt pathway to elicit their effect on the clock period, we assayed transcription of the Wnt target *cAxin2* in the caudal chicken PSM. We found that 100 μM XAV939 ([Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), 10 μM Roscovitine ([Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}; n = 31/41) and 10 μM DRB ([Figure 2---figure supplement 1F](#fig2s1){ref-type="fig"}; n = 29/42) robustly down-regulated transcription of *cAxin2* in the caudal chicken PSM, compared to the DMSO control. These data raise the possibility that the effects of these reagents on the segmentation clock are via inhibition of Wnt activity. However, the increased phosphorylation of β-catenin at Ser33, Ser37, Thr41 observed with XAV939, which serves as a readout of Wnt inhibition, was not observed following exposure to 10 μM Roscovitine ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; n = 5/6) or 10 μM DRB ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}; n = 4/4), suggesting that the mechanism by which these CDK inhibitors inhibit transcription of *cAxin2* is not through the inhibition of canonical Wnt signalling. However, alternative mechanisms of Wnt inhibition exist that do not lead to an increase in β-catenin phosphorylation and thus we cannot rule out an effect of CDK inhibition via changes in Wnt signalling.

Exposure to cyclin dependent kinase inhibitors increases the level of cNICD in the PSM {#s2-7}
--------------------------------------------------------------------------------------

Having shown that Wnt inhibition or exposure to a panel of CDK inhibitors robustly delays the pace of the segmentation clock, a key question is whether or not there is a common mechanism underlying these observations. We thus investigated whether levels of NICD were perturbed by the CDK inhibitor treatments. Using the same assay as described above, one pool of PSMs was cultured for 3 hr in DMSO and the contralateral halves were cultured in the inhibitor. Both pools were then cultured for an hour in the presence of cycloheximide before Western Blot analysis ([Figure 4C](#fig4){ref-type="fig"}). Remarkably, and in agreement with model predictions, we observed that the level of cNICD protein was again increased significantly in the presence of Roscovitine ([Figure 4D](#fig4){ref-type="fig"}, lanes 7, 8; n = 9/10), DRB ([Figure 4D](#fig4){ref-type="fig"}, lanes 9, 10; n = 6/8) and PHA-767491 ([Figure 4D](#fig4){ref-type="fig"}, lanes 11, 12; n = 2/2) compared to the corresponding DMSO control pool (See [Table 1](#tbl1){ref-type="table"}). Again, even in the absence of cycloheximide ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), levels of cNICD in the chicken PSM were consistently higher when treated with Roscovitine ([Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}; n = 5/7), and DRB ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}; n = 4/6) compared to respective DMSO control lysates (See [Table 1](#tbl1){ref-type="table"}). Thus, Roscovitine, DRB and PHA-767491 treatments all increase the level of cNICD protein in the chicken PSM, just as they all delay oscillations of the Notch target gene *cLfng*. Hence, taken together the data with the Wnt and CDK inhibitors fulfil the predictions of the model that increased levels of NICD will be associated with an increase to the periodicity of clock gene oscillations.

XAV939 and the CDK inhibitors extend the clock period in chick leading to formation of fewer somites {#s2-8}
----------------------------------------------------------------------------------------------------

To verify the extent to which the period had been extended in the presence of each of the reagents, we performed a time course of the fix and culture assay. We determined the time needed for one full oscillation by extending the time in culture for the cultured half until the expression profiles matched in the two explants, with an extra somite having formed in the cultured explant. Untreated control pairs completed one full oscillation and made an extra somite in 90 min whereas exposure to the reagents resulted in an oscillation period of approximately 120 min (n = 8 for each inhibitor and for DMSO; [Figure 2---figure supplement 3E-J](#fig2s3){ref-type="fig"}).

A prediction of the clock and wave-front model of somitogenesis is that a longer clock period will result, assuming a constant wave-front speed, in the formation of fewer, larger somites in a given time. Hence we analysed somite number in drug-treated explants cultured for an extended period of 6 hr and found that fewer somites formed in the presence of Roscovitine (n = 9, mean number = 2.11), DRB (n = 9, mean number = 1.94), PHA-767491 (n = 10, mean number = 2.5) and XAV939 (n = 7, mean number = 3.14) compared to DMSO controls (n = 15, mean number = 4.25). Additionally, using the fix and culture assay to confirm that the clock is still operating under treatment conditions, we observed that *Lfng* expression is still dynamic after the 6 hr culture period ([Figure 5D--H](#fig5){ref-type="fig"}; n = 5/5 for each reagent and for DMSO). Moreover, once the somites from the determined region of the PSM had segmented we observed a significant stepwise increase in somite size along the anteroposterior axis in the embryos cultured in the presence of XAV939, Roscovitine, PHA-767491 or DRB as compared to DMSO control treated embryos ([Figure 5A--C,I--R](#fig5){ref-type="fig"}). Taken together, these data demonstrate that XAV939, Roscovitine, PHA-767491 and DRB treatments all result in an extension of the clock period and the formation of fewer, larger somites.10.7554/eLife.05842.012Figure 5.Length of newly formed somites are increased following long-term treatment with inhibitors.(**A**--**C**): Graphs showing log base 2 (fold) changes in 2 consecutive somite length ratios between the average somite lengths for the first (+1), second (+2), and third (+3) formed somites following treatment initiation in the presence of DMSO, XAV939, Roscovitine, PHA767491 or DRB. T-tests were performed to test the null hypothesis that the mean somite length ratio is the same as in DMSO controls. The null hypothesis was rejected in the starred cases (p \< 0.005) with the following p values XAV = 0.0211; Rosc = 0.0002; Pha = 0.0001; DRB = 0.0007 (**D**--**H**) Bissected chick caudal explant pairs subjected to the fix and culture assay after 6 hr treatment in the presence of DMSO, XAV939, Roscovitine, PHA767491 or DRB. In each case the cultured side showed *cLfng* expression had advanced. (**I**--**M**) In situ hybridisation of *cTbx6* on whole embryos following 6 hr treatment in the presence of either DMSO, XAV939, Roscovitine, PHA767491 or DRB. Asterix = newly formed somite(s) during culture, line = length of most recently formed somite, scale bar = 100 μm**.** (**N**--**R**) High magnification image of the samples in (**I**--**M**). XAV939 treated embryos do not form as clearly defined boundaries as the other inhibitor treated embryos. (F) = following cycle.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.012](10.7554/eLife.05842.012)

Exposure to XAV939, and the CDK inhibitors increases the half-life of cNICD in the PSM {#s2-9}
--------------------------------------------------------------------------------------

Given the delays inherent to Notch and Delta-like1 (DLL1) trafficking and their intercellular interaction, it is possible that new NICD could be produced even in the presence of CHX, based on signalling through receptors that were made prior to the initiation of CHX treatment. Thus, if XAV939, Roscovitine or DRB increased the production of DLL1 or Notch1, the observed increase in NICD might be secondary to increased signalling, rather than a result of changes in protein turnover. To address this possibility, we replaced the 1h CHX treatment with a 1h LY411575 treatment to specifically block production of new NICD, repeated the assay and measured levels of cNICD by Western Blot analysis. Thus, one pool of PSMs was cultured for 3 hr in DMSO and the contralateral halves were cultured in XAV939, Roscovitine or DRB. Both pools were then cultured for an hour in the presence of LY411575 before Western Blot analysis ([Figure 4F](#fig4){ref-type="fig"}). Remarkably, we observed that the level of cNICD protein was again increased in the presence of XAV939 ([Figure 4F](#fig4){ref-type="fig"}, lane 4), Roscovitine ([Figure 4F](#fig4){ref-type="fig"}, lane 6) and DRB ([Figure 4F](#fig4){ref-type="fig"}, lane 8) compared to the corresponding DMSO control pools ([Figure 4F](#fig4){ref-type="fig"}, lanes 3, 5, 7) where NICD levels were severely diminished due to endogenous NICD degradation plus exposure to LY411575 for an hour. As a control, explants cultured in explant media for 3h followed by 1h LY411575 showed severe depletion of NICD compared to the corresponding DMSO pool of contralateral halves ([Figure 4F](#fig4){ref-type="fig"}, lanes 1, 2). These data demonstrate that the higher levels of cNICD observed following exposure to the inhibitors is not due to increased production of NICD.

In order to test the hypothesis that the observed increased level of NICD following inhibitor treatment is due to modification of the half-life of NICD, we sought to quantify the half-life of endogenous cNICD in the PSM. Pools of 9 explants from corresponding embryos were prepared as above but cultured in the presence or absence of a given inhibitor. Following an initial 30 min exposure to cycloheximide in both pools to inhibit new protein synthesis, the decay of cNICD protein was monitored as follows: in one pool protein lysate was immediately prepared whilst in the other, culture for an additional 30--60 min was performed before lysate was prepared ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} and data not shown). Thus, the temporal decay of cNICD was quantified (see [Figure 6A](#fig6){ref-type="fig"}). Notably the measured profiles are of the form predicted by [Equation (4)](#equ11){ref-type="disp-formula"}.10.7554/eLife.05842.013Figure 6.cNICD half-life in the PSM is increased after exposure to Roscovitine, DRB and PHA-767491.(**A**): Endogenous cNICD levels analysed by Western Blot (after normalisation to alpha tubulin loading control) in PSM explants cultured initially in the presence of each reagent for 3 hr and subsequently in the presence of inhibitor plus cycloheximide for an additional 30 min before the time-course. Panels show log transformation on repeated data. The half life is proportional to the inverse of the inferred slope ([Equation \[4\]](#equ4){ref-type="disp-formula"}). (**B**) Bar chart showing the half-life of cNICD in each condition. Asterix represents statistically significant differences p \< 0.05. (**C**) Left Panel: Treatment in the presence (+) or absence (−) of MLN4924 for 3 hr reveals that the inhibitor treated explant has lagging expression of *cLfng* compared to the control contralateral explant. Right panel: After 3 hr in the presence of MLN4924 one PSM explant was fixed while the other was treated for another 45 min, showing *cLfng* expression is still dynamic in the presence of this inhibitor. (**D**) Following the assay described in [Figure 4](#fig4){ref-type="fig"}, levels of cNICD, normalised to levels of alpha tubulin, in the chick PSM pools are highly increased in the presence of MLN4924. Western Blot analysis of pooled PSM lysates from half PSM explants treated '+' or '−' MLN4924 reveals levels of phosphorylated β-catenin are increased in the chick PSM after 3 hr treatment with MLN4924.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.013](10.7554/eLife.05842.013)10.7554/eLife.05842.014Figure 6---figure supplement 1.Roscovitine, PHA-767491 and DRB treatment increases the level of cNICD in the chick PSM.Figure 6---figure supplement 1(**A**--**B**): Western Blot analysis to monitor the decay of cNICD protein: after 3 hr treatment with the reagents the pools of 9 explants were exposed to cycloheximide for 30 min to inhibit new protein synthesis, and subsequently the decay of cNICD protein was monitored whereby one pool was removed from culture and protein lysate prepared while the corresponding pool was cultured for an additional 30--60 min before lysate also prepared. The +/− lanes with Cycloheximide (CHX) show that levels of cNICD fall dramatically in the absence of de novo protein synthesis in the presence of this reagent.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.014](10.7554/eLife.05842.014)

From these data we infer the NICD half-life and find that it takes the value 11.87 (+/− 4.97) minutes in untreated control embryos ([Figure 6A](#fig6){ref-type="fig"}; n = 5). Strikingly, in the DRB, Roscovitine and PHA-767491 treated explants, the half-life of cNICD protein is 29.59 (+/− 9.29), 22.01 (+/− 7.04) min, and 36.41 (+/− 8.88) min, respectively ([Figure 6A,B](#fig6){ref-type="fig"}; n = 4 for each inhibitor). These data show that DRB, Roscovitine and PHA-767491 treatments all significantly increase the half-life of cNICD protein in the chick PSM. Thus, the data support the model prediction that an increased NICD half-life results in a longer clock period.

Inhibition of SCF (SKP1- CUL1-F-box protein) E3 ubiquitin ligase complexes results in delayed clock oscillations and higher levels of NICD {#s2-10}
------------------------------------------------------------------------------------------------------------------------------------------

Whilst the measurements of NICD half-life are consistent with the model prediction that increased NICD half-life will result in longer period oscillations and increased levels of NICD, we reasoned that if NICD half-life is controlling the clock period, we ought to be able to increase the clock period by targeting NICD turnover.

NICD stability is known to be regulated by the Skp, Cullin, F-box^Sel10/FBXW7^ (SCF ^Sel10/FBXW7^) E3 ubiquitin ligase complex ([@bib24]). We tested whether turnover of NICD within the PSM affects the clock pace by repeating the half-embryo assay in the presence or absence of MLN4924 which inactivates SCF E3 ubiquitin ligase complexes by suppressing neddylation of Cullin-1 ([@bib59]). As a control, we analysed levels of phosphorylated β-catenin which is also targeted for ubiquitination and degradation by the SCF E3 ubiquitin ligase complex. As expected, exposure of PSM explants to 1 μM MLN4924 led to increased levels of phosphorylated β-catenin ([Figure 6D](#fig6){ref-type="fig"}). Notably, exposure of PSM explants to 1 μM MLN4924 caused a delay in the pace of *Lfng* dynamic expression across the PSM ([Figure 6C](#fig6){ref-type="fig"}; n = 16) and increased levels of cNICD ([Figure 6D](#fig6){ref-type="fig"}; n = 3; [Table 1](#tbl1){ref-type="table"}). The fix and culture assay confirmed that *cLfng* expression was still oscillatory in the PSM at this concentration ([Figure 6C](#fig6){ref-type="fig"}; n = 16). Exposure to higher concentrations of MLN4924 (10--100 μM) resulted in progressively greater increases in the level of cNICD but abolished dynamic *Lfng* expression across the PSM (data not shown). Notably, the mathematical model predicts that oscillations are only supported within a limited range of NICD (and Hes7) half-lives (See [Figure 1](#fig1){ref-type="fig"}). These data support the central thesis provided in this paper: a balance between positive and negative regulators is necessary for oscillations of the somitogenesis clock.

Reducing NICD production rescues the phase pattern changes and increased level of cNICD in the PSM caused by exposure to XAV939, and the CDK inhibitors {#s2-11}
-------------------------------------------------------------------------------------------------------------------------------------------------------

Taken together, the data presented thus far support the hypothesis that increasing the half-life of NICD elevates levels of NICD and lengthens the period of oscillations. In order to directly address the causality between increased NICD stability and the change in pace of oscillations, we attempted to rescue the effect of the inhibitors by modifying NICD production in the PSM.

We performed a titration curve with the gamma secretase inhibitor LY411575 to reduce but not remove NICD production. PSM pools were cultured for 3 hr in DMSO and their contralateral halves cultured in different concentrations of LY411575. In the presence of 5 nM LY411575, cNICD levels decreased significantly compared to the corresponding DMSO pool ([Figure 7A](#fig7){ref-type="fig"}, lanes 1, 2), while in the presence of 1 nM or 0.1 nM LY411575, the levels of cNICD protein were similar to control DMSO treated contralateral PSMs ([Figure 7B](#fig7){ref-type="fig"}, lanes 1, 2, [Figure 7C](#fig7){ref-type="fig"}, lanes 1, 2). Hence, pools of PSMs were cultured for 3 hr in DMSO and the contralateral halves cultured in 10 μM Roscovitine together with 5 nM, 1 nM or 0.1 nM LY411575 prior to Western Blot analysis. The higher levels of NICD usually seen in the presence of Roscovitine alone ([Figure 7D](#fig7){ref-type="fig"}) are rescued by 1 nM LY411575 such that they resemble the levels of NICD in the corresponding DMSO pool ([Figure 7B](#fig7){ref-type="fig"} lanes 3, 4). These findings concur with the predictions clearly proposed by our model ([Figure 1H](#fig1){ref-type="fig"}). In contrast, 10 μM Roscovitine together with 5 nM LY411575 showed severely depleted levels of cNICD compared to the corresponding DMSO pool ([Figure 7A](#fig7){ref-type="fig"} lanes 3, 4), resembling the effect of 5 nM LY411575 alone (compared to [Figure 7A](#fig7){ref-type="fig"}, lanes 1, 2). 10uM Roscovitine together with 0.1 nM LY411575 showed increased levels of cNICD compared to the corresponding DMSO pool, resembling the effect of 10 μM Roscovitine alone ([Figure 7C](#fig7){ref-type="fig"}, lanes 3, 4, compared to [Figure 7D](#fig7){ref-type="fig"}).10.7554/eLife.05842.016Figure 7.Exposure to 1 nM LY411575 rescues the increased levels of cNICD caused by 10 μM Roscovitine.Endogenous cNICD levels analysed by Western Blot (after normalisation to alpha tubulin loading control) in PSM explant pools cultured for 3 hr in the presence (+) or absence (−) of (**A**) 5 nM LY411575 (lane 1,2); 10 μM Roscovitine together with 5 nM LY411575 (lane 3,4) or (**B**) 1 nM LY411575 (lane 1,2); 10 μM Roscovitine together with 1 nM LY411575 (lane 3,4) or (**C**) 0.1 nM LY411575 (lane 1,2); 10 μM Roscovitine together with 0.1 nM LY411575 (lane 3,4) (**D**) or 10μM Roscovitine alone.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.016](10.7554/eLife.05842.016)

We repeated these experiments and analysed the effect upon the mRNA expression of the clock gene *cLfng*. 5 nM LY411575 severely reduced *cLfng* expression in the PSM ([Figure 8A](#fig8){ref-type="fig"}; n = 4/4) whereas *cLfng* appeared largely unaffected in the presence of 1 nM or 0.1 nM LY411575, compared to the control explant ([Figure 8B,C](#fig8){ref-type="fig"}; n = 22/25; n = 11/13, respectively). We then assessed whether we could rescue the changes in phase patterns brought about by Roscovitine, DRB or XAV939 by reducing NICD production through exposure to 1 nM or 0.1 nM LY411575. Strikingly, we observed a rescue of the phase pattern in a significant number of explants cultured in the presence of Roscovitine, DRB or XAV939 together with 1 nM LY411575 ([Figure 8G--I](#fig8){ref-type="fig"}; n = 15/39, n = 8/20, n = 6/15, respectively) compared to explants cultured in the presence of Roscovitine, DRB or XAV939 alone which show a delay to the phase pattern ([Figure 8D--F](#fig8){ref-type="fig"}; n = 14/15, n = 9/10, n = 7/8, respectively). Explants cultured in the presence of Roscovitine or XAV939 together with 0.1 nM LY411575 did not rescue the delay caused by these inhibitors ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"} and data not shown; n = 0/9; n = 0/4).10.7554/eLife.05842.017Figure 8.Exposure to 1 nM LY411575 rescues the delay in clock gene oscillations caused by Roscovitine, DRB and XAV939.Bissected chick or mouse caudal explant pairs treated '−' or '+' inhibitor and then analysed by insitu hybridisation for *Lfng* mRNA expression: (**A**--**C**) Treatment of chick PSM explants in the presence (+) or absence (−) of 5 nM LY411575 (**A**), 1 nM LY411575 (**B**), 0.1 nM LY411575 (**C**) for 3 hr reveals that 5 nM LY411575 severely downregulates *cLfng* expression whereas 1 nM and 0.1 nM do not appear to change levels or domain of *cLfng* expression. (**D**--**F**): Treatment of chick PSM explants in the presence (+) or absence (−) of Roscovitine (**D**), DRB (**E**) or XAV939 (**F**) for 3 hr reveals that '+' explants have lagging expression of *cLfng*, with one less somite formed than the '−' explants. (**G**--**I**): Treatment of chick PSM explants in the presence (+) or absence (−) of 1 nM LY411575 together with Roscovitine (**G**), DRB (**H**) or XAV939 (**I**) for 3 hr reveals that 1 nM LY411575 rescues the delay in clock gene oscillations caused by these three inhibitors such that the *cLfng* expression domains in the '−' and '+' explants are very similar. The red arrowheads identify the somites formed during the in vitro culture period of the assay. (P) = previous cycle.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.017](10.7554/eLife.05842.017)10.7554/eLife.05842.018Figure 8---figure supplement 1.0.1 nM LY411575 does not rescue the delay in oscillation caused by Roscovitine.Bissected chick caudal explant pair treated '−' or '+' 10μM roscovitine and 0.1 nM LY411575 and then analysed by in situ hybridisation for the Notch target gene *cLfng* reveals *cLfng* mRNA expression is delayed in the treated side as compared to the control after 3 hr treatment. Black arrows indicate somites.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.018](10.7554/eLife.05842.018)

These very striking data showing a rescue of both NICD levels and the delay to the clock oscillations provide strong evidence that increased half-life and higher levels of NICD brought about by Roscovitine, DRB or XAV939 underlie the delay to clock gene oscillations observed on exposure to the inhibitors ([Figure 9](#fig9){ref-type="fig"}).10.7554/eLife.05842.015Figure 9.A schematic illustration depicting how modification of NICD stability may cause a delay to the period of the oscillations.(**A**) Schematic showing the competition between molecules of Hes7 and NICD for binding to the promoter of a clock gene. Exposure to Roscovitine, XAV939 or DRB causes increased stability and levels of NICD and thus NICD occupies the promoter for longer than in the wild-type situation, thereby prolonging the oscillation period. Exposure to 1 nM LY411575 together with Roscovitine, XAV939 or DRB reduces the level of NICD production offsetting the increased stability which rescues the delay. t1 = delay due to transcription of Hes7 and Notch; t2 = the delay due to translation of Hes7; t3 = delay due to translation of Notch and subsequent ligand dependent production of NICD. (**B**) Graphical model depicting how modifying the stability of NICD may cause a delay to the period of the oscillations by delaying the time-point at which proportional levels of NICD and Hes7 allow switching of promoter occupancy of these two factors.**DOI:** [http://dx.doi.org/10.7554/eLife.05842.015](10.7554/eLife.05842.015)

Discussion {#s3}
==========

Mathematical models that invoke the mechanism of delayed negative feedback have successfully explained numerous experimental observations of the somitogenesis clock (e.g., [@bib41]; [@bib48]; [@bib29], [@bib2]; [@bib25]). These models are an excellent example of how a relatively simple mathematical framework can provide insight into the behaviour of a multi-component, multi-scale, nonlinear biological system. An elegant prediction of the models is that the period of the somitogenesis clock can be approximated as a sum of the constituent delays and the half-lives of negative regulators. However, whilst numerous studies have shown that genetic modification of clock components can modify the clock period, relatively little work has been published on whether half-lives of clock proteins have the predicted effect. Moreover, the models neglect the potential role of positive regulators of clock gene expression. In this study we combine experimental manipulation and mathematical modelling to begin to explore these issues.

In order to investigate the role of positive regulators of the somitogenesis clock, we modified previous frameworks to account for the role of NICD in the somitogenesis clock. In the model, NICD and the inhibitory clock protein compete to activate and repress the transcription of a clock gene, respectively. Notably, the release of NICD is a multi-cellular phenomenon involving the periodic and coordinated expression of cell surface proteins ([@bib5]). In order to avoid describing each of the constituent components, here we consider a model of a single cell oscillator and assume that NICD is released periodically in a manner that is coupled to the transcription of other clock genes ([@bib5]). This formalism allows us to avoid explicitly modelling the temporal dynamics of Delta and Notch across cell populations and focus solely on investigating the role of the half-life of the positive regulator. The predicted outcome of the model is that increasing the half-life of NICD elevates levels of NICD and lengthens the period of oscillations in addition to increasing levels of the inhibitory clock protein. These effects can be rescued by decreasing the production rate of NICD.

In order to explore whether these predictions can be validated experimentally, we have further explored an intriguing phenotype whereby the application of a diverse range of small molecule inhibitors results in a clear, robust delay in the pace of *Lfng* oscillations across the chick and mouse PSM. We find that for each of the small molecule inhibitor treatments, the levels of the positive regulator, NICD, are elevated and NICD half-life is increased. When interpreted within the framework of the proposed model, these data support the hypothesis that treatment with the small molecule inhibitors results in an increased half-life of the positive regulator NICD, which elevates the levels of NICD, delays the clock, and results in the formation of fewer larger somites. In contrast, when interpreted within the framework of the proposed model, the data do not support the hypothesis, for instance: that the drug treatments solely modify the half-lives of negative regulators of the somitogenesis clock, such as Hes7. We also demonstrate experimentally, in agreement with model predictions, that both the delay in the pace of *Lfng* oscillations across the PSM and the elevated levels of the positive regulator, NICD, resulting from exposure to the small molecule treatments can be rescued by decreasing NICD production.

In this study we observe delays in the PSM phase pattern in the presence of small molecule inhibitors that are rescued by Delta-Notch signalling inhibitors. From these observations we infer that the autonomous frequency of individual oscillations is perturbed as a result of increased NICD stability. Nevertheless, it is also possible that the effect of increasing the NICD half-life is to alter tissue scale properties of the frequency gradient profile (e.g., increasing its rostro-caudal velocity or steepness would result in a greater proportion of cells in the PSM experiencing lower frequencies and thus observations of delayed phase patterns). Regardless of this detail, the premise of this study remains intact: positive as well as negative regulators of the somitogenesis clock can regulate its period.

We note that the inclusion of both positive and negative feedback into the somitogenesis clock model introduces the possibility of interesting nonlinear phenomena that may have relevance to the somitogenesis clock. For instance, Tsai et al. have shown that the inclusion of positive and negative feedback loops can result in the attainment of a wide frequency range over a small range in amplitudes ([@bib65]). This point is potentially relevant in the context of somitogenesis, where a frequency gradient is thought to underlie the striking phase waves that traverse the rostro-caudal axis.

Wnt inhibition increases levels and half-life of cNICD and extends the period of the clock {#s3-1}
------------------------------------------------------------------------------------------

Previous reports have suggested that inhibition of Shh signalling slows the segmentation clock in the chick PSM ([@bib56]). In this study, we clearly show that, in our hands, inhibiting the Shh pathway does not affect clock pace or the level of cNICD in the chick PSM within the timeframe of our assay. A possible reason for this discrepancy with Resende et al. is that we culture explant pairs for 3 hr whereas they observed delays to somite formation, in the absence of Shh signalling, only after 7.5 hr culture and alterations to clock gene expression after 4.5 hr culture. One possible explanation for the later arising effects they observe on the pace of the clock and somite formation is that they that are indirect secondary effects arising from Shh inhibition. In contrast, we report Wnt inhibition, within a 3 hr time frame, elicited by exposure to XAV939, increases the half-life of NICD in the chick and mouse PSM, leading to elevated NICD levels and a clear and robust prolonged period of clock gene oscillations and somite formation. Intriguingly, Gonzalez et al. previously reported exposure of mouse PSM explants to LiCl, which acts to inhibit GSK3B, lengthens the period of Hes7 oscillations in the mouse PSM. However, the authors report this effect may rather be via LiCl activation of the MapK pathway which is important for Hes expression in the PSM ([@bib23]), since more specific approaches to elevate Wnt signalling have been shown not to change the endogenous period of the segmentation clock ([@bib1]; [@bib21]). Moreover, Gonzalez et al. found the Wnt inhibitor CKI-7 delayed clock gene oscillations in the mouse PSM, in line with our own observations ([@bib21]; [@bib23]).

CDK inhibitors roscovitine, DRB and PHA-767491 regulate the period of clock gene oscillations {#s3-2}
---------------------------------------------------------------------------------------------

We demonstrate that three CDK inhibitors, Roscovitine, DRB and PHA-767491, also increase the half-life of cNICD and delay the pace of *Lfng* oscillations at concentrations that have no significant effect on cell proliferation. At higher concentrations of inhibitors that did affect proliferation, the oscillations of *Lfng* expression were abolished. Importantly, these data separate the effects of the inhibitors on the segmentation clock from those on the cell cycle. This finding is consistent with the 'clock and wavefront' model of somitogenesis, rather than a cell cycle based model ([@bib9]; [@bib61]).

Tight control of the half-life of NICD, a positive regulator of oscillatory clock gene expression, appears key to regulating the clock period {#s3-3}
---------------------------------------------------------------------------------------------------------------------------------------------

A striking finding is the fact that these very different pharmacological reagents share distinctive phenotypic outputs: increased levels and half-life of NICD and extended period of the clock gene oscillations. This raises the compelling prospect that these effects are causally linked. Recent data showing that Notch1 protein is dynamically and periodically expressed in the chick and mouse PSM in a Notch dependent fashion ([@bib5]) demonstrate that Notch1/NICD is itself part of a positive feedback loop. We experimentally validate the prediction that under conditions where half-life of NICD is increased, the period of the clock is extended. Our data thus expand upon previous models by highlighting the necessity for an added level of regulation, namely the strict regulation of the half-life for the positive input signal, NICD. Hence, it appears equally important to balance levels of both positive and negative input to correctly regulate the periodicity of clock gene oscillations. This result is similar to observations made in *Nrarp*-null mice, which display increased NICD levels in the PSM and a decrease in somite and vertebral body number although the pace of clock gene oscillations and somite size was not assessed ([@bib36]).

Our data with the neddylation inhibitor MLN4924 further substantiate the hypothesis that extended NICD half-life is causally linked to the extended clock period, given that this reagent, which acts via a completely distinct molecular mechanism, nevertheless leads to the same phenotypic output as the Wnt and CDK inhibitors. Thus, in addition to the expected higher levels of NICD in the PSM of MLN4924 treated explants, we saw a corresponding increase in the period of *Lfng* oscillations, as seen for XAV939, Roscovitine, DRB and PHA-767491 treated explants. In addition to elevating levels of NICD, exposure to MLN4924 elevates levels of phosphorylated β-catenin within PSM lysates. Since we show that Wnt inhibition can lead to elevated NICD levels and a delay to clock oscillations, this raises the possibility that the effects of MLN4924 are mediated via Wnt inhibition rather than directly via NICD turnover. However, we propose this is unlikely since in the absence of a degradation pathway the elevated levels of phosphorylated β catenin may in fact continue to participate in target gene transcription. Indeed, APC mutant lines which allow β catenin phosphorylation but are defective in ubiquitination are oncogenic, consistent with the idea that phosphorylated β catenin can indeed activate target genes ([@bib68]). Thus, we propose that the extended period of the clock seen following exposure to MLN4924 is due to the elevated levels of NICD brought about via inhibition of NICD degradation. Exposure to higher concentrations of this inhibitor leads to correspondingly higher levels of NICD in PSM explants and this accompanies a loss of dynamic *Lfng* expression. A similar correlation is seen in PSM explants exposed to increasing concentrations of Roscovitine, DRB, PHA-767491. It has previously been shown that overexpression or complete loss of Notch signalling abolishes clock gene oscillations and causes severe segmentation defects ([@bib51]; [@bib15]; [@bib16]). These data, together with previous reports investigating the effect of modulating protein levels of key clock components ([@bib29]; [@bib36]), indicate that there is a tolerance window for the degree of variance in levels of positive and negative input which will still allow for oscillatory gene expression. These experimental findings are consistent with the predictions of our model which also clearly predict that there is a window within which variations in half-life of both Hes7 and NICD will allow for oscillations. Taken together, our computational and experimental data show that slowing, as opposed to stopping, of the segmentation clock gene oscillations may be brought about through transient and/or partial stabilisation of Notch activity.

The rescue of both phase pattern changes and NICD levels elicited by exposure to both low concentrations of LY411575 together with Roscovitine, DRB or XAV939 provides compelling evidence that increased half-life and higher levels of NICD brought about by these inhibitors underlies the delay to clock gene oscillations ([Figure 9](#fig9){ref-type="fig"}).

Following exposure to Roscovitine, DRB, PHA-767491 and XAV939, the Western Blot data reveal an additional band for NICD at a slightly lower molecular weight in some of the inhibitor treated samples as compared to the control treated samples. This observation is characteristic of an increase in abundance of a variant of a protein which lacks small post-translational modifications such as phosphate groups. This shift may therefore represent the loss of phosphorylation marks which have been shown to be important for NICD regulation and degradation ([@bib19]; [@bib35]). These data support the idea that post translational modification events may regulate the stability of NICD that could then directly affect the pace of the segmentation clock.

XAV939, Roscovitine, DRB and PHA-767491 may directly affect NICD half-life through post translational modification of NICD {#s3-4}
--------------------------------------------------------------------------------------------------------------------------

As alluded to above, post translational modifications may underlie the effects of the 4 reagents that each modulate NICD half-life and clock period. We demonstrate that XAV939 treatment elevates levels of GSK3B-mediated phosphorylated β catenin in the PSM and it is possible that it might equally facilitate GSK3B mediated phosphorylation of NICD which has previously been reported to affect NICD stability ([@bib14]; [@bib35]). It is noteworthy that the effect of this phosphorylation event on NICD stability is likely to be context dependent since different groups have reported this modification can increase or decrease NICD stability and it is not known if any of these interactions occur in the PSM ([@bib18]; [@bib14]; [@bib35]). Similarly, it is possible that the CDK inhibitors modulate CDK-mediated phosphorylation of NICD which has also been reported to affect NICD stability ([@bib19]). Interestingly, exposure to specific CDK7, CDK8 or CDK9 inhibitors did not yield the delayed oscillation phenotype or increased levels of NICD and half-life of NICD in the chick PSM (data not shown). These data are somewhat surprising given that there are published reports describing a role for CDK8 in phosphorylating and thereby destabilising NICD. Indeed, CDK8-mediated phosphorylation in the PEST domain of NICD is required to target this protein for ubiquitination and subsequent degradation by the E3 ligase FBW7 ([@bib19]). Whilst it is possible that this mode of regulation of NICD stability by this specific CDK does not occur in the PSM, we acknowledge that it is also possible that the effect on pace and cNICD stability are only made apparent when inhibiting a combination of these activities as seen with Roscovitine, DRB and PHA-76749. It is important to note that an alternative explanation for the lack of effect of specific CDK7, CDK8, or CDK9 inhibitors is that the effect of Roscovitine, DRB and PHA-767491 may be through inhibition of a different set of kinases. The precise identification of the kinase(s) involved in destabilising cNICD will require further investigation.

XAV939, roscovitine, DRB and PHA-767491 may indirectly affect NICD half-life and the clock period through transcriptional regulation of NICD-stability regulators {#s3-5}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

It is also formally possible that the common outcome of exposure to these four reagents to influence the pace of the clock involves regulation at the transcriptional level. Roscovitine is known to have highest efficacy against CDK2/CyclinE, CDK5, CDK7/CyclinH and CDK9/CyclinT ([@bib46]) whereas DRB and PHA-767491 reduce the kinase activities of CDK7/CyclinH and CDK9/CyclinT towards Serine 2 and Serine 5 on the C-terminal domain (CTD) of RNA pol II. Exposure to DRB, Roscovitine, or PHA-767491 leads to a reduction in Ser5 RNA pol II phosphorylation ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}) which is required to promote initiation of transcription as RNA pol II moves away from the gene promoter ([@bib38]) but it is also associated with 'poised' genes bound by both Ser5 phosphorylated RNA pol II and Polycomb repressor complexes ([@bib6]). Thus, one possibility is that reduced Ser5 phosphorylation of RNA pol II may leave some 'poised' genes in the PSM in a more repressed state. Importantly, certain gene transcripts are more susceptible to DRB treatment than others ([@bib69]; [@bib8]; [@bib66]) and indeed we find not all gene transcripts in the PSM are down-regulated by these inhibitors (e.g., *cLfng* and *cHairy2* expression is delayed in the PSM but not down-regulated). Thus, the effects of these inhibitors may be to modify certain 'poised' genes to a more repressed state that specifically include genes encoding factors required for destabilising NICD.

Given that XAV939 elicits the same phenotypic output as exposure to the CDK inhibitors it is conceivable that all four reagents affect the transcription of some common genes; some involved in regulating the clock while others not; indeed we identified one gene commonly affected by all 4 reagents namely *Gli1* (known to be regulated by Wnt signalling in the neural tissue and somites ([@bib49]), [Figure 2---figure supplement 1E--G](#fig2s1){ref-type="fig"}). For this particular gene we show it is unlikely to be involved in clock regulation ([Figure 3](#fig3){ref-type="fig"}). However, a transcriptomic analysis of common target genes would allow this possibility to be fully explored to identify genes co-regulated by these reagents which potentially encode regulators of NICD stability in the PSM.

Finally, a recent report has beautifully demonstrated that in zebrafish embryos the rate of tissue shortening, in addition to the periodicity of clock gene oscillations, is important in determining the periodicity of segmentation ([@bib58]). Further analyses are required to investigate if this is a conserved feature in all vertebrate species. That analysis notwithstanding, our data nevertheless clearly show that the pace of the segmentation clock itself has a strong influence upon the pace of somite formation since significantly fewer somites are formed within a given time-frame when the pace of clock gene oscillations and NICD stability are affected. In conclusion, our data suggest that the stability and turnover of NICD is inextricably linked to the regulation of the pace of clock gene expression across the PSM.

Materials and methods {#s4}
=====================

Experimental Procedures {#s4-1}
-----------------------

### Chick culture {#s4-1-1}

Fertilized chick (*Gallus* gallus) embryos from Winter Farm, Cambridge, UK, were incubated for approximately 40 hr at 38°C 5% CO~2~ to yield embryos between Hamburger Hamilton (HH) stages 10--12 as judged by somite number and morphology. Explants were prepared as previously described ([@bib54]). In brief, for the half-embryo assay: the caudal end of the chicken embryo is isolated to contain the most caudal somite pairs and the tail tissues. The isolated tail is then bisected down the midline along the neural tube to produce two identical left and right half-PSM explants which allows an internal control from the same embryo with which to compare the oscillation phase of *cLfng* expression by in situ hybridisation, following culturing of the two halves in various culture conditions. The following small molecule inhibitors were typically used at the given concentrations and dissolved in Dimethyl sulfoxide (DMSO) unless otherwise stated: 150 nM LY411575 unless otherwise stated (generated in house, University of Dundee; [@bib16]; [@bib5]), 1 μM MLN4924 (generated in house, University of Dundee); 20 μM Cycloheximide (Tocris Bioscience; dissolved in ethanol); 100 μM XAV939 (Tocris Bioscience); 25--50 μM Cyclopamine (Calbiochem); 10 μM Roscovitine (Calbiochem); 10 μM 5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) (Sigma, United Kingdom); 1 μM PHA-767491 (kind gift from Nathanael Gray, [HARVARD.EDU](http://HARVARD.EDU)). Titration assays were performed to establish the lowest concentration that abolishes expression of control target genes. For Fix and culture: both half-PSM explants were treated with inhibitor but while one was removed from culture after 3 hr ('fix'), the other side was cultured for an additional 45 min ('culture') which corresponds to half of the usual 90 min cycle for a complete oscillation of *cLfng* in the chicken PSM. Variations include culturing the 'culture' side for '90' or '120' min to determine the length of an oscillation. For the Western Blot analysis half-PSMs from 9 embryos were cultured in DMSO control vehicle and the corresponding 9 half-PSMs cultured in the presence of a small molecule inhibitor. Following 3 hr of culture, both pools were treated with 20 μM Cycloheximide for an additional 30 min before protein lysates were prepared simultaneously. For the half-life assay: half-PSMs from 9 embryos were pooled and both pools were cultured in each of the reagents for 3 hr and following 30 min exposure to cycloheximide, the decay of cNICD protein was monitored in the presence of these inhibitors by lysing PSM explants at different time points. Experiments were conducted in strict adherence to the Animals (Scientific Procedures) Act of 1986 and UK Home Office Codes of Practice for use of animals in scientific procedures.

### In situ hybridisation {#s4-1-2}

Whole-mount in situ hybridisations utilising exonic and intronic probes were performed as described ([@bib21]).

### Phospho-HistoneH3 staining {#s4-1-3}

Fixed PSM explant tissue was proteinase K (Roche) treated and fixed (4% formaldehyde in PBS, 2 mM EGTA, 0.1% glutaraldehyde \[Sigma\]) prior to washing in PBST. Explants were then blocked in 2% bovine serum albumin (BSA) in PBST for 2 hr at room temperature. Anti-phospho histone-H3 antibody (Upstate) was then added at 10 μg/ml and the samples incubated at 4°C overnight. Specimens were then washed for 10 hr in a minimum of three changes of PBST before the Alexa-fluor488 conjugated mouse anti-rabbit antibody (Invitrogen) was added at 2 μg/ml in PBST and left overnight at 4°C. Samples were then washed for 10 hr in PBST with a minimum of 3 changes of solution. Explants were then mounted on SuperFrost microscope slides (VWR) using Hydromount (National Diagnostics) and imaged using either a compound fluorescence microscope (Leica DM5000 B) or a Zeiss 710 confocal microscope. Images were quantified using Volocity v6.0.1 imaging software (Perkin Elmer) and either t-tests or Mann--Whitney tests performed using SigmaPlot v12.0 software.

### NucView apoptosis staining {#s4-1-4}

+/− treated explant pairs were cultured for 2 hr (chicken) or 3 hr (mouse) before the addition of 5 μM NucView 488 Caspase-3 Assay Kit for live cells (Biotium) and cultured for an additional 1 hr. Samples were then fixed for 1 hr at 4°C in 4% formaldehyde/PBS. Samples were then washed into PBST and explant pairs were mounted on superfrost slides (VWR) in Prolong Gold anitfade reagent (Molecular Probes) for imaging on a Zeiss 710 confocal microscope. Quantification of NucView cell staining was performed using Volocity v6.0.1 imaging software (Perkin Elmer) and statistical analyses done using either t-tests or Mann--Whitney tests with Sigmaplot v12.0 software.

### Generation of cNICD antibodies {#s4-1-5}

The peptide VLVSRKRRREHGC (corresponding to residues 1792--1803 of the chicken NOTCH1 protein, with the addition of a C-terminal cysteine residue for coupling) was coupled separately with Keyhole Limpet Hemocyanin (KLH) and BSA using m-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) and dialysed into PBS. The affinity purification of the cNICD antibody was achieved by putting the third bleed serum from the rabbit which had been immunised with the peptide on an affinity column which had been previously prepared by coupling the cNICD peptide with vinylsulfone activated sepharose. The purified antibody was then dialysed into PBS.

### Western Blot analysis {#s4-1-6}

Pooled samples of 9 Chick embryo half-PSM explants were prepared by pipetting treated tissue in 90 μl mixture containing lysis buffer (50 mM Tris Hydrochloride pH7.5, 150 mM Sodium chloride \[NaCl\], 1 mM ethylenediaminetetraacetic acid \[EDTA\], 1 mM ethylene glycol tetraacetic acid \[EGTA\], 10 mM Sodium pyrophosphate, 10 mM Sodium glycerophosphate, 50 mM Sodium fluoride, 1 mM Sodium orthovanadate, 0.3% 3-\[{3-cholamidopropyl} dimethylammonio\]-1-propanesulfonate \[CHAPS\], 1 mM Benzamidine, 0.1% β-mercaptoEtOH, 0.1 mM phenylmethanesulfonylfluoride \[PMSF\]), supplemented with 1x Sample Reducing Agent and 1x LDS Sample Buffer (Life Technologies). Samples were then reduced at 95°C for 5 min and allowed to cool briefly before loading 20 μl of each sample onto 4--12% Bis--Tris acrylamide gels (Life Technologies). Gels were then Blotted using standard molecular techniques and the resultant nitrocellulose membranes (Whatman) were blocked in 5% milk in TBS--0.1% Tween 20 (TBST). Membranes were treated overnight at 4°C in one of the following antibodies diluted in 5% BSA in TBST: 1:1000 rabbit anti-chick NICD (University of Dundee); 1:1000 rabbit anti-mouse NICD (Cell Signalling); 1:1000 rabbit anti-phospho S33, S37, T41 β-catenin (Cell Signalling); 1:5000 rabbit anti-total β-catenin (I. Nathke); 1:1000 rabbit-anti Fbw7 (Abcam); 1:1000 rabbit anti-mouse Hes7 (University of Dundee, generated as [@bib4]); 1:200 rat-anti phospho S2 RNA pol II (Chromotek); 1:200 rat-anti phospho S5 RNA pol II (Chromotek); 1:200 rat-anti total RNA pol II (Chromotek); 1:5000 mouse anti-α-tubulin (Abcam). Membranes were then incubated with the appropriate secondary antibody (HRP) in 5% milk in TBST and standard ECL revelation (Pierce).

### Statistical approach {#s4-1-7}

It was hypothesized that half-life of NICD would alter as a function of the treatments applied. Small samples and short time series limited the ability to develop a robust empirical model that could be broadly applied; as such each half-life was developed on a per treatment basis with linear modelling. Natural log transformations were performed on concentrations such that a slope and intercept could be reasonably estimated. Those with significant slopes are reported in [Figure 6](#fig6){ref-type="fig"}. Statistical analyses were conducted in R 3.2.0 ([@bib55]).

### Mathematical model {#s4-1-8}

We develop a minimal model of the somitogenesis clock with the goal of exploring the roles of both negative and positive feedback of clock products on clock dynamics. The model has two dependent variables: numbers of cytoplasmic clock protein, *p*(*t*), and NICD, *n*(*t*). Given that cytoplasmic clock protein and NICD act as a transcriptional repressor and activator, respectively, we assume that the rate of production of clock gene products is proportional to$$f\left( p,n \right) = \frac{\left( \frac{n}{K_{n}} \right)}{1 + \left( \frac{p}{K_{p}} \right)^{2}}\,,$$where *K*~*p*~ is an IC50 constant and *K*~*n*~ is a constant that determines a scale for NICD activation. We note that the competition between activation and repression of transcription by NICD and clock protein, respectively, that is encapsulated by [Equation (1)](#equ1){ref-type="disp-formula"} plays a key role in the model behaviour.

Assuming linear decay of cytoplasmic protein at rate *k*~2~, the rate of change of numbers of cytoplasmic clock protein with respect to time is given by the delay differential equation$$\frac{\text{  }dp}{dt} = k_{1}f\left( p\left( t - T_{1} \right),n\left( t - T_{1} \right) \right) - k_{2}p\left( t \right),\,$$where the delay *T*~1~ represents the time that elapses between protein/NICD influencing transcriptional activation and the effect on cytoplasmic protein levels (i.e. the sum of transcription, splicing, export and translation delays).

Whilst it is well established that NICD undergoes pulsatile dynamics in the PSM, Notch1 and Dll1 undergo qualitatively similar behaviour and Notch is a target of Notch signalling ([@bib5]). The production of NICD within a given cell is therefore a multicellular process with multiple oscillatory regulatory inputs. We capture the periodic production of NICD by making the simplifying assumption that the production rate of NICD is the same as that of clock protein but with a longer delay, *T*~2~, to account for the trafficking of Notch1 and Dll1 to the membrane and their transactivation. Assuming that NICD decays at rate *k*~4~, we obtain$$\frac{dn}{dt} = k_{3}f\left( p\left( t - T_{2} \right),n\left( t - T_{2} \right) \right) - k_{4}n\left( t \right).$$

We use this model ([Equations (1)](#equ1){ref-type="disp-formula"}-[(3)](#equ3){ref-type="disp-formula"}) to investigate how the decay kinetics of both positive and negative regulators of clock transcription can influence the oscillator period. Further model details can be found in the [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}.

### Measuring the half-life of endogeneous NICD {#s4-1-9}

In order to measure the half-life of endogeneous NICD, the following experimental protocol is followed: 9 embryos are dissected along their midlines with contralateral halves placed in two pools (A and B). The pools are initially cultured for 3 hr, either in the presence of a drug or control medium, and then for 30 additional minutes in the presence of a translation inhibitor. The samples from pool A are homogenised and the total amount of NICD in a given pool is quantified. Pool B is then cultured for a further time *τ* (30, 40 or 60 min), homogenised and NICD is quantified.

Consider Pool A and let *A*~*i*~(*t*) represent the amount of NICD in the i^th^ PSM at time *t* (where *t*=0 represents some arbitrarily chosen position in the periodic NICD cycle). The (experimentally measurable) total amount of NICD in the whole of Pool A is given by$$\overline{A} = \sum\limits_{i}^{N}A_{i}\left( t \right),$$where *N* is the number of samples in the pool. Similarly, the total amount of NICD in Pool B is given by$$\overline{B} = \sum\limits_{i}^{N}B_{i}\left( t \right).$$

As the samples in Pools A and B are paired (contralateral halves), *B*~*i*~(*t*)=*A*~*i*~(*t*+*τ*), where *τ* is the additional culture time for Pool B, hence$$\overline{B}\left( \tau \right) = \sum\limits_{i}^{N}A_{i}\left( t + \tau \right).$$

Calculating the ratio of total amount of NICD in Pool B to that of Pool A, we define$$F\left( \tau \right) = \frac{\overline{B}\left( \tau \right)}{\overline{A}}.$$

As each of the nine tissue samples can be thought of as being random samples from some underlying periodic NICD time series, *A*(*t*), the above sums can be thought of as representing a naive Monte Carlo integration. Hence the experimentally calculated *F*(*τ*) is an approximation to$$F\left( \tau \right) = \frac{\int_{0}^{T}A\left( t + \tau \right)dt}{\int_{0}^{T}A\left( t \right)dt},$$where*T* represents the period of the oscillations. The question now is whether the half-life of NICD can be inferred by experimentally measuring *F*(*τ*) at different values of *τ*.

In the case where *A*(*t*) is periodic, both integrals will tend to the same value and the measure tends to one. In contrast, if production of NICD ceases, and NICD undergoes only linear decay, *A*(*t*+*τ*)=*A*(*t*)*e*^−*βτ*^, where *β* is the NICD degradation constant. In this case,$$F\left( \tau \right) = \frac{\int_{0}^{T}A\left( t \right)e^{- \beta\tau}dt}{\int_{0}^{T}A\left( t \right)dt} = e^{- \beta\tau},$$and the measure decays exponentially. Combining, if production stops at some time *t*~*s*~ after the experiment begins, we obtain the measure$$F\left( \tau \right) = \left\{ \begin{matrix}
{1,\,\tau < t_{s}} \\
{e^{- \beta{(\tau - t_{s})}},\text{  }\tau \geq t_{s}.} \\
\end{matrix} \right.$$

Taking natural logs we obtain$$\ln\left( {F\left( \tau \right)} \right) = \left\{ \begin{matrix}
{0,\,\tau < t_{s}} \\
{- \beta\left( \tau - t_{s} \right),\,\tau \geq t_{s}.} \\
\end{matrix} \right.\,$$

Hence linear regression allows the determination of the decay constant *β* and the corresponding half-life is calculated to be ln 2/*β*.

Whilst the above equation predicts the experimental measure in the case of a large number of samples, it is notable that the effective finite sampling of the integrals could result in large measured deviations from mean behaviour. In fact, noting that NICD dynamics are strongly pulsatile, the above integrals will likely be dominated by the number of sampled NICD peaks in a given pool.
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Thank you for sending your work entitled "A balance of positive and negative regulators determines the pace of the segmentation clock" for consideration at *eLife*. Your article has been evaluated by Janet Rossant (Senior Editor) and three reviewers.

The reviewers all agreed that there was considerable merit in your study and that the concept of a positive regulator of the somite clock was an interesting one. However, there was one major concern. The experimental work demonstrates nicely a correlation between NICD levels and stability and period length. Nonetheless, all reviewers were concerned that you had not really proven a causal relationship between elevated NICD half-life and extension of the oscillation period.

There was a quite extensive discussion on this issue, and the reviewers were not sure exactly how you could prove your hypothesis. Some ideas were introducing a low level of RNAi to Notch1 to reduce Notch levels or treating with a gamma-secretase inhibitor to reduce NICD production or to increase FBXW7 levels. Alternately, another hypothesis discussed was to show that the clock period can be returned to normal by making NICD less stable (despite treating with a CDK or Tankyrase inhibitor). Other possibilities raised were locally raising NICD levels or changing half-life by removing the PEST domain. We realize that these are not necessarily the right experiments, and therefore would like to give you the option to respond to this criticism. Please take into account the major concerns raised by reviewers 1 and 2, appended below.

Reviewer 1:

1\) The percentage of embryos where *cLfng* expression is delayed after (for example) Wnt inhibition is almost certainly statistically significant, but in the absence of data from control embryos (both halves cultured in DMSO) and some statistical comparison, this cannot be confirmed. The authors should already have this data.

2\) For figures looking at NICD levels and half-life following drug treatment, it is not entirely clear to me that treatment with cycloheximide alone will prevent production of new NICD in explants. Given the delays inherent in Notch and DLL1 trafficking, cell surface presentation, and interactions, it seems possible that new NICD could be produced even in the presence of CHX, based on signaling through receptors that were made prior to initiation of CHX treatment. Thus, if any of the inhibitors increased the production of DLL1 or NOTCH1, for example, then the increases in NICD observed might be secondary to increased signaling, rather than a result of changes in protein turnover. Control experiments where inhibition of Notch signaling was initiated at the time of CHX treatment could address this concern, and provide additional support to the thesis that the effects the authors observe are due to changes in NICD half-life.

3\) The use of *p* values in [Figure 4](#fig4){ref-type="fig"} legend indicates that multiple pools were assessed and the Western Blot bands were quantified. The details of this process, as well as the averages and standard deviations of the values and the statistical analysis used should be described. Further, I don\'t find the phosphoserine 5 controls showing activity of CDK inhibitors in [Figure 2--figure supplement 1B](#fig2s1){ref-type="fig"} extremely convincing. Details of quantification of Western Blots might help here as well. The authors should have this data.

4\) From the images provided in [Figure 5](#fig5){ref-type="fig"}, it is not clear how "normal" the longer somites formed in the presence of various inhibitors actually are. Given that changes in clock synchrony also can affect somite size and morphology, the reader needs to have a clear idea of how (if) somite production might be perturbed by these treatments. Images that focus more closely on the region of interest to let the reader interpret morphology, and perhaps in situ analysis with markers that would delineate somite compartments would lend support to the authors' conclusions.

5\) Data showing that MLN4924 increases phospho-β catenin are shown in [Figure 6](#fig6){ref-type="fig"}, but as far as I could tell, are not discussed? Since the authors claim that Wnt inhibition can on its own increase NICD levels and half-lives, this data should be at least acknowledged and put in some kind of context.

Reviewer 2:

1\) The experimental work nicely shows a correlation between NICD levels and stability and period length. It is however not clear if there is a causal relationship between elevated NICD half-life and extension of the oscillation period. The last set of experiments presented (subsection "Inhibition of SCF (SKP1- CUL1-F-box protein) E3 ubiquitin ligase complexes results in delayed clock oscillations and higher levels of NICD"), aiming at inhibiting the SCF E3 ubiquitin ligase complex is extremely important to address this issue. However, it should be extended to show that the inhibitor does not work through inhibition of the Wnt pathway, as is the case of the previous inhibitors. Otherwise the order of events remains unclear. Related to this, the last panel of [Figure 6D](#fig6){ref-type="fig"}, which is not described in the Results section (and should be), suggests that levels of phosphorylated β catenin are elevated following MLN4924 treatment. This should be explained.

2\) In many ways, [Figure 1](#fig1){ref-type="fig"} is essential to this manuscript. We feel it could be enhanced to facilitate the reading of the manuscript and understanding of the model and predictions. [Figure 1A and B](#fig1){ref-type="fig"} are not visually explicit enough to understand: a) the relationship between the clock protein, NICD, the feedback loops and the output on the oscillation period; b) how this model differs from the previous ones (Figure A could be replaced by the previous models); c) what the assumptions underlying this new model are. In addition, and maybe in the Experimental Procedures section, a statement explaining how the model can fit both the chicken and mouse somitogenesis, which oscillations for instance have a different period, would be useful.

3\) [Figure 1C-H](#fig1){ref-type="fig"} should be explained in a bit more detail, since this is the basis for understanding the rationale behind the experiments. The period on the top of the plots C-E correspond to what? In D and E how much are the half-lives of NICD and Hes7 increased? Maybe it should be stated clearly what the used values are and that the loss of oscillations in [Figure 1D](#fig1){ref-type="fig"} corresponds to red region in [Figure 1F](#fig1){ref-type="fig"} near the solid line that is the limit of oscillations.

4\) The competition relationship between NICD and the inhibitory clock protein to activate and repress transcription of a clock gene respectively (what parameter/properties considered?) impinges on the predictions of the model and interpretation of [Figure 1D](#fig1){ref-type="fig"}, which postulates that elevated NICD half-life results in more clock protein, and should be better spelled out. In addition, depending on the ability of the clock protein to be a potent transcription inhibitor, having NICD longer around but not much more NICD protein may not have much of an impact. It would be useful to explicit which parameter(s) in the mathematical model reflect this aspect.

5\) The description of the approach to measure the half-life is a bit confusing and hard to follow with regard to the equations. *A*~*i*~*(t)* is the amount of NICD in both pools A and B. "t" is a free parameter. We suggest for the second equation in the subsection "Measuring the half-life of endogeneous NICD": B_bar(*τ*)=A_bar(t+τ)=sum... and F(τ)=A_bar(t+τ)/A_bar(τ). This is more coherent with the integral form of F(τ) in the fourth equation.

Maybe it would be useful to have a profile sketch for A as a function of t. If we understand correctly, as long as τ\<*t*~*s*~, A is equal to a constant value A~0~, then as we reach to *t*~*s*~, A(*t*) decays exponentially. Using this sketch, it will be easier to understand that for τ\<=*t*~*s*~, A(t) = A(t+τ), else A(t+τ)=A(t)e^--^β^τ^). We also suggest that the first sentence of the second paragraph changes to "Letting *A*~*i*~*(t)* be the amount of NICD in the i^th^ tissue sample at time (*t*). We define the experimentally measurable sum in pool A as..."

6\) What is T in the integral form of F(τ) in the subsection "Measuring the half-life of endogeneous NICD", the clock period?

7\) [Figure 6A](#fig6){ref-type="fig"}: It should be mentioned that the vertical axis is log F(τ), the units of the horizontal axis is minutes. The label seems to be "τ" and not "t". It would be useful to add at the end of the legend (A) that the inverse of the slope gives the half-life (data presented in [Figure 6B](#fig6){ref-type="fig"}). I don\'t understand where does the 0.5C~0~=C~0~e-^slope\ t^ relationship come from. In the main text, Log F(τ)=--β(Τ--*t*~*s*~). From the slopes of [Figure 6A](#fig6){ref-type="fig"} we get the values in [Figure 6(B)](#fig6){ref-type="fig"} and from the intercept we should be able to get *t*~*s*~ (which seems to be of the order of 10 minutes). Can the authors comment on this (and why this has not been used to calculate *t*~*s*~?).

8\) [Figure 4D](#fig4){ref-type="fig"} and [Figure 6](#fig6){ref-type="fig"} seem to point to different values for NICD half-life. The 2nd lane in [Figure 4D](#fig4){ref-type="fig"} indicates that all NICD proteins are cleared in 3 hours; the 4th lane indicates that significant residual NICD remains 1h after its production has been blocked. Could the authors explicit how these experimental results fit with the calculated half-life indicated in the subsection "Exposure to XAV939, and the CDK inhibitors increases the half-life of cNICD in the PSM"?

In addition, it would be very informative to visualize (in embryos) if the NICD half-life is homogenously increased in the somites and presomitic mesoderm, as its impact on the oscillation period is expected in a very defined spatial window.

9\) Impact of SHH inhibition on the oscillation. It is a bit unsettling to only find in the Discussion a reference to the 2010 PNAS paper claiming the opposite results, and not upfront in the Results section. In addition, one would have liked to read possible reasons for the discrepancy.

10.7554/eLife.05842.021

Author response

*The reviewers all agreed that there was considerable merit in your study and that the concept of a positive regulator of the somite clock was an interesting one. However, there was one major concern. The experimental work demonstrates nicely a correlation between NICD levels and stability and period length. Nonetheless, all reviewers were concerned that you had not really proven a causal relationship between elevated NICD half-life and extension of the oscillation period*.

There was a quite extensive discussion on this issue, and the reviewers were not sure exactly how you could prove your hypothesis. Some ideas were introducing a low level of RNAi to Notch1 to reduce Notch levels or treating with a gamma-secretase inhibitor to reduce NICD production or to increase FBXW7 levels. Alternately, another hypothesis discussed was to show that the clock period can be returned to normal by making NICD less stable (despite treating with a CDK or Tankyrase inhibitor). Other possibilities raised were locally raising NICD levels or changing half-life by removing the PEST domain. We realize that these are not necessarily the right experiments, and therefore would like to give you the option to respond to this criticism.

We have given the referees' concerns careful consideration and conducted a key experiment to address the major issue that has been raised (i.e. causality of increased NICD stability and change in the pace of the clock -- please see below for details). In short we titrated the concentration of the gamma secretase inhibitor LY411575 so as to reduce the elevated levels of NICD that were induced by the Rosc/DRB/XAV treatment and found that the clock delay phenotype is reversible. We believe that this dose-dependent rescue using a drug that is highly specific to NICD production in the cytoplasm provides strong evidence in support of the main thesis of our study that the increased NICD stability induced by Rosc/DRB/XAV treatment leads to a change in the pace of the clock. Moreover, the results from the rescue are consistent with the predictions of the mathematical model (see [Figure 1H](#fig1){ref-type="fig"}).

In addition, we have responded to all other comments, added 4 new figures, a table and new data to [Figures 4 and 5](#fig4 fig5){ref-type="fig"}. Moreover, we have refined the mathematical model so that it has fewer variable and parameters and can better illustrate the major thesis of this study.

A key issue raised is that of causality between NICD stability and the change in pace of oscillations. We have used a small molecule approach to rescue the phenotype as follows:

LY411575 is a specific gamma-secretase inhibitor that blocks the release of NICD into the cytoplasm. We titrated its concentration so as to reduce but not remove NICD production in an attempt to offset the stability caused by Roscovitine/DRB/XAV939. The aim was to attempt to rescue the delay induced by the Roscovitine/DRB/XAV939 treatment.

In the initial draft of the manuscript we showed that Roscovitine, DRB or XAV939 delay the clock (approximately 95% chick; 90% mouse). In this revised draft we show that this phenotype is rescued in a significant proportion of the explants (30--40%) by the addition of 1 nM LY411575. Higher concentrations of LY411575 together with Roscovitine result in severe downregulation of *Lfng* mRNA expression whilst lower concentrations of LY411575 (0.1 nM) do not rescue the delay effect of Roscovitine ([Figure 8](#fig8){ref-type="fig"} and [Figure 8--figure supplement 1](#fig8s1){ref-type="fig"}). Thus we have identified a dose-dependent rescue using an inhibitor that is specific to NICD production within the cytoplasm.

Additionally, we have run Western Blots to show that the higher levels of NICD, usually seen in the presence of Roscovitine alone, are rescued by adding in 1 nM LY411575 ([Figure 7](#fig7){ref-type="fig"}). Given the well-established role of LY411575 in preventing NICD cleavage, we argue that this rescue is a particularly striking result that provides extremely strong support for the central thesis proposed in this study: that increased half-life and higher levels of NICD brought about by Roscovitine, DRB or XAV939 underlie the delay to clock gene oscillations observed on exposure to these inhibitors.

Furthermore, the result of this rescue is in agreement with the prediction of the mathematical model (see [Figure 1H](#fig1){ref-type="fig"}) which suggests that decreasing production of NICD in a background of longer half-life NICD will result in rescue of the phenotype (i.e. it is the ratio of production to decay rates that is the important parameter, hence reducing the decay rate can be offset by reducing the production rate).

We note that in order to demonstrate causality, the reviewers' suggested the following experiments:

i) Introduce a low level of RNAi to Notch1 to reduce Notch levels;

ii) Treat with gamma-secretase inhibitor to reduce NICD production;

iii) Increase FBXW7 levels;

iv\) Show the clock period can be returned to normal by making NICD less stable despite treating with a CDK or tankyrase inhibitor;

v) Locally raise NICD levels; and

vi) Change half-life by removing the PEST domain.

We gave each of these suggestions careful consideration. However, a technical problem with a number of the suggestions is that they require electroporation of a construct into the PSM. Despite huge experience working on this system in our lab, we find that this technique targets cells in a mosaic fashion and is at best 50% efficient. In such an experiment we would have no control over the amount of construct taken up.  Moreover, some of the suggested constructs would then need to compete with the endogenous Notch protein.

In our experience with this system, an effective way to affect all cells in a temporally controlled manner is through the use of small molecule inhibitors. In the future we would of course aim to identify the mechanism by which NICD is stabilised and generate a mouse that phenocopies this mechanistically in order to conclusively demonstrate causality. However, that is out of the remit of this manuscript.

Reviewer 1:

*1) The percentage of embryos where* cLfng *expression is delayed after (for example) Wnt inhibition is almost certainly statistically significant, but in the absence of data from control embryos (both halves cultured in DMSO) and some statistical comparison, this cannot be confirmed. The authors should already have this data*.

We have included these data. In DMSO treated explant pairs an asymmetric pattern of *cLfng* expression was rarely seen (n = 2/18) showing asymmetry, data not shown) and as such the effects of XAV939 on *cLfng* expression could not be attributed to DMSO or natural variability in expression or to the assay itself.

*2) For figures looking at NICD levels and half-life following drug treatment, it is not entirely clear to me that treatment with cycloheximide alone will prevent production of new NICD in explants. Given the delays inherent in Notch and DLL1 trafficking, cell surface presentation, and interactions, it seems possible that new NICD could be produced even in the presence of CHX, based on signaling through receptors that were made prior to initiation of CHX treatment. Thus, if any of the inhibitors increased the production of DLL1 or NOTCH1, for example, then the increases in NICD observed might be secondary to increased signaling, rather than a result of changes in protein turnover. Control experiments where inhibition of Notch signaling was initiated at the time of CHX treatment could address this concern, and provide additional support to the thesis that the effects the authors observe are due to changes in NICD half-life*.

We appreciate this comment and have conducted this experiment. We have replaced the 1h CHX treatment with 1h LY411575 treatment following exposure to Roscovitine, DRB or XAV939 and we then conducted the western to look at levels of NICD. We observe a very similar result to that seen with CHX: In contrast to explants cultured in explant media for 3h followed by 1h LY411575 which show severe depletion of NICD, we see that explants cultured in Roscovitine, DRB or XAV939 for 3h followed by 1h LY411575 show remarkably higher levels of NICD (see [Figure 4](#fig4){ref-type="fig"}). This data together with the half-life assay demonstrates that the higher levels are due to increased stability rather than increased production of NICD.

*3) The use of* p *values in* [*Figure 4*](#fig4){ref-type="fig"} *legend indicates that multiple pools were assessed and the Western Blot bands were quantified. The details of this process, as well as the averages and standard deviations of the values and the statistical analysis used should be described. Further, I don\'t find the phosphoserine 5 controls showing activity of CDK inhibitors in* [*Figure 2--figure supplement 1B*](#fig2s1){ref-type="fig"} *extremely convincing. Details of quantification of Western Blots might help here as well. The authors should have this data*.

We have included a table with these details (please see [Table 1](#tbl1){ref-type="table"}).

*4) From the images provided in* [*Figure 5*](#fig5){ref-type="fig"}*, it is not clear how "normal" the longer somites formed in the presence of various inhibitors actually are. Given that changes in clock synchrony also can affect somite size and morphology, the reader needs to have a clear idea of how (if) somite production might be perturbed by these treatments. Images that focus more closely on the region of interest to let the reader interpret morphology, and perhaps* in situ *analysis with markers that would delineate somite compartments would lend support to the authors' conclusions*.

We have added new panels to [Figure 5](#fig5){ref-type="fig"} in which we present higher magnification images of the somites formed during the culture period.

*5) Data showing that MLN4924 increases phospho-β catenin are shown in* [*Figure 6*](#fig6){ref-type="fig"}*, but as far as I could tell, are not discussed? Since the authors claim that Wnt inhibition can on its own increase NICD levels and half-lives, this data should be at least acknowledged and put in some kind of context*.

We have reported the effect of MLN4924 upon phospho-β catenin in both the Results and Discussion. Phosphorylated β catenin is targeted for ubiquitination and degradation by the E3 ligase complex which is targeted by MLN4924. Thus, it is expected that exposure to this inhibitor leads to increased levels of phospho- β catenin. However, we propose the effects of MLN4924 on levels of NICD and disruption of phase patterns are not via indirect effects upon Wnt signaling for the following reasons: elevated levels of phospho βcatenin are indicative of Βcatenin molecules that would normally be decommissioned from participating in Wnt signaling but which are prevented from being degraded by MLN4924. Moreover, elevated levels of phospho βcatenin could in principle continue to participate in target gene transcription in the absence of a degradation pathway. If so it would mean MLN4924 potentially leads to elevated levels of Wnt signalling. Indeed, there are some APC mutant lines which allow βcatenin phosphorylation but are defective in ubiquitination ([@bib68] JBC). Given that these mutations are oncogenic, it would seem that phosphorylated βcatenin can indeed activate target genes. Even if phospho βcatenin cannot participate in target gene transcription, the phosphorylation decommissioning event is independent of MLN4924 and is thus happening at physiological levels and so again is not indicative of an inhibitor mediated block to Wnt signalling. Thus, we propose it is unlikely the extended period of the clock seen following exposure to MLN4924 is via Wnt inhibition but that rather it is due to the elevated levels of NICD brought about via inhibition of NICD degradation.

Reviewer 2:

*1) The experimental work nicely shows a correlation between NICD levels and stability and period length. It is however not clear if there is a causal relationship between elevated NICD half-life and extension of the oscillation period. The last set of experiments presented (subsection "Inhibition of SCF (SKP1- CUL1-F-box protein) E3 ubiquitin ligase complexes results in delayed clock oscillations and higher levels of NICD"), aiming at inhibiting the SCF E3 ubiquitin ligase complex is extremely important to address this issue. However, it should be extended to show that the inhibitor does not work through inhibition of the Wnt pathway, as is the case of the previous inhibitors. Otherwise the order of events remains unclear. Related to this, the last panel of* [*Figure 6D*](#fig6){ref-type="fig"}*, which is not described in the Results section (and should be), suggests that levels of phosphorylated β catenin are elevated following MLN4924 treatment. This should be explained*.

See response above to reviewer 1, point 5.

*2) In many ways,* [*Figure 1*](#fig1){ref-type="fig"} *is essential to this manuscript. We feel it could be enhanced to facilitate the reading of the manuscript and understanding of the model and predictions.* [*Figure 1A and B*](#fig1){ref-type="fig"} *are not visually explicit enough to understand: a) the relationship between the clock protein, NICD, the feedback loops and the output on the oscillation period; b) how this model differs from the previous ones (Figure A could be replaced by the previous models); c) what the assumptions underlying this new model are. In addition, and maybe in the Experimental Procedures section, a statement explaining how the model can fit both the chicken and mouse somitogenesis, which oscillations for instance have a different period, would be useful*.

[Figure 1A and B](#fig1){ref-type="fig"} have been improved in order to provide a better graphical representation of the molecular oscillator. The diagrams have been annotated to provide insight into how changing model parameters affects model outputs. We welcome the suggestion of replacing Figure A but we wanted to illustrate to the reader that the release of NICD is a multicellular phenomenon that we are simplifying in this model. We have added an extended discussion of how the model is related to other models in the Discussion section.

We have simplified the model structure so that we can focus specifically on half-lives of activators/inhibitors of transcription. The model assumptions are explained in greater detail when the model is introduced.

The questions of how chicken-clock period is different to that of mouse is a very interesting one. Moreover, it is not properly understood how even in a single PSM the period of individual oscillators varies as a function of axial position!

However, this work does show that modifying the half-life of positive activators of clock genes can produce a shift in period that is of similar magnitude to the chick-mouse difference. Of course, this could be an important mechanism in setting species-specific period and controlling the oscillation rate along the axis but we do not currently have the data to address this question so have not commented upon it.

*3)* [*Figure 1C-H*](#fig1){ref-type="fig"} *should be explained in a bit more detail, since this is the basis for understanding the rationale behind the experiments. The period on the top of the plots C-E correspond to what? In D and E how much are the half-lives of NICD and Hes7 increased? Maybe it should be stated clearly what the used values are and that the loss of oscillations in* [*Figure 1D*](#fig1){ref-type="fig"} *corresponds to red region in* [*Figure 1F*](#fig1){ref-type="fig"} *near the solid line that is the limit of oscillations*.

We thank the referee for pointing out the lack of detail. The period is the period of the oscillations for a given parameter set. Parameter values are now presented in the legend. The oscillating/no oscillating regions in parameter space are now better annotated.

*4) The competition relationship between NICD and the inhibitory clock protein to activate and repress transcription of a clock gene respectively (what parameter/properties considered?) impinges on the predictions of the model and interpretation of* [*Figure 1D*](#fig1){ref-type="fig"}*, which postulates that elevated NICD half-life results in more clock protein, and should be better spelled out*.

Upon introducing the model we state clearly that the competition between inhibitor/activator is a key model feature. The production function f is now introduced up front and we discuss that the assumption is that the balance of activator and inhibitor set the production rate.

*In addition, depending on the ability of the clock protein to be a potent transcription inhibitor, having NICD longer around but not much more NICD protein may not have much of an impact. It would be useful to explicit which parameter(s) in the mathematical model reflect this aspect*.

We have conducted a range of numerical experiments to classify model behaviour. What we suggest in this study is that the balance between activator/inhibitor is crucial. So making the half-life of inhibitor too large will result in loss of oscillations. This is now made clear for example in [Figure 1F](#fig1){ref-type="fig"} (increasing inhibitor half-life results in damped oscillations).

*5) The description of the approach to measure the half-life is a bit confusing and hard to follow with regard to the equations.* A~i~(t) *is the amount of NICD in both pools A and* ***B****. "t" is a free parameter. We suggest for the second equation in the subsection "Measuring the half-life of endogeneous NICD": B_bar(τ)=A_bar(t+τ)=sum... and F(τ)=A_bar(t+τ)/A_bar(τ). This is more coherent with the integral form of F(τ) in the fourth equation*.

*Maybe it would be useful to have a profile sketch for A as a function of t. If we understand correctly, as long as τ\<*t~s~*, A is equal to a constant value A*~*0*~*, then as we reach to* t~s~*, A(t) decays exponentially. Using this sketch, it will be easier to understand that for τ\<=*t~s~*, A(t)=A(t+τ), else A(t+τ)=A(t)e*^*--*^*β*^*τ*^*). We also suggest that the first sentence of the second paragraph changes to "Letting* A~i~(t) *be the amount of NICD in the* i^th^ *tissue sample at time (*t*). We define the experimentally measurable sum in pool A as..."*

We thank the referee for these queries. We apologise as there was typo in the first equation and variables were not defined clearly enough. These issues have now been addressed.

There are nine different PSMs. Each are split in two with a half from each going into Pool A and Pool B. We define *A*~*i*~*(t)* to be the amount of NICD in the *i*^*th*^ sample in Pool A and *B*~*i*~*(t)* to be the amount of NICD in the *i*^*th*^ sample in Pool B. As pool B is sampled for *τ*  extra minutes we can write *B*~*i*~*(t)* = *A*~*i*~*(t + τ*). Summing over all the samples we get to the experimentally measurable quantity and from that we can infer the half-life.

6\) What is T in the integral form of F(τ) in the subsection "Measuring the half-life of endogeneous NICD", the clock period?

T is the period of the clock. This has now been amended. Apologies for any confusion caused by this omission.

*7)* [*Figure 6A*](#fig6){ref-type="fig"}*: It should be mentioned that the vertical axis is log F(τ), the units of the horizontal axis is minutes. The label seems to be "τ" and not "t". It would be useful to add at the end of the legend (A) that the inverse of the slope gives the half-life (data presented in* [*Figure 6B*](#fig6){ref-type="fig"}*). I don\'t understand where does the 0.5C*~*0*~*=C*~*0*~*e-*^*slope\ t*^ *relationship come from. In the main text, Log F(τ)=--β(Τ--*t~s~*). From the slopes of* [*Figure 6A*](#fig6){ref-type="fig"} *we get the values in* [*Figure 6(B)*](#fig6){ref-type="fig"} *and from the intercept we should be able to get* t~s~ *(which seems to be of the order of 10 minutes). Can the authors comment on this (and why this has not been used to calculate* t~s~*?)*.

We thank the reviewer for pointing out these errors. The labels should be τ. This has been changed. The *0.5C*~*0*~*=C*~*0*~*e-*^*slope\ t*^ has been removed and we now refer to the main text for the correct formula.

The referee is correct that *t*~*s*~ takes a value of the order of tens of minutes. As stated in the definition of F(\\τ), the measure ought to be necessarily noisy in the first few minutes when NICD is still potentially being produced. Owing to experimental restrictions NICD levels were samples at later times and it is from these data that we infer the half-life. Hence we are in the regime where t\>*t*~*s*~.

*8)* [*Figure 4D*](#fig4){ref-type="fig"} *and [Figure 6]{.ul} seem to point to different values for NICD half-life. The 2nd lane in* [*Figure 4D*](#fig4){ref-type="fig"} *indicates that all NICD proteins are cleared in 3 hours; the 4th lane indicates that significant residual NICD remains 1h after its production has been blocked. Could the authors explicit how these experimental results fit with the calculated half-life indicated in the subsection "Exposure to XAV939, and the CDK inhibitors increases the half-life of cNICD in the PSM"?*

[Figure 4D](#fig4){ref-type="fig"} shows different exposures of NICD for the WB panels, chosen to best highlight the difference between NICD levels in '+' and '--' corresponding pools. For calculating the half-life of NICD following treatments the WB images of all the time points were taken at the same exposure for calculation.

*In addition, it would be very informative to visualize (in embryos) if the NICD half-life is homogenously increased in the somites and presomitic mesoderm, as its impact on the oscillation period is expected in a very defined spatial window*.

Despite our very best efforts to secure this data it has eluded us and we have found the antibody particularly tricky to work with by immunocytochemistry. We have put a huge amount of effort, time and reagents into optimising the protocol by either paraffin section, cryostat section and whole mount immunocytochemistry on explants but to no avail. A clear reliable signal is attained only very rarely. For this particular experiment the difficulty is compounded by the fact that we need to obtain a clear strong signal in pairs of explants to glean any information (two half-embryos from the same embryos where one is treated "+" and one treated "--" the inhibitor).

*9) Impact of SHH inhibition on the oscillation. It is a bit unsettling to only find in the Discussion a reference to the 2010 PNAS paper claiming the opposite results, and not upfront in the Results section. In addition, one would have liked to read possible reasons for the discrepancy*.

We mention the Resende paper in subsections "Wnt inhibition delays the pace of *cLfng* oscillations in the chick and mouse PSM" and "Shh inhibition does not delay the pace of *cLfng* oscillations in the chick PSM" and we have broadened our Discussion.

[^1]: These authors contributed equally to this work.

[^2]: These authors also contributed equally to this work.

[^3]: demarcates a statistically significant difference.

[^4]: Densitometry was performed on Western Blots and the fold change of cNICD or mNICD in the + inhibitor treated sample relative to the corresponding DMSO control was adjusted to the relative change in the tubulin loading control. The given statistical test was used to compare the average value for each assay to a fixed fold-change value = 1 (i.e. no change) and a p-value obtained.
